Screener / SEC EDGAR /CIK 0000885590 /10-K filed Feb 19, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Pharmaceuticals

Bausch Health Companies Inc. BHC

Compare with peers Embed
Earnings releases

Latest results release: Oct 28, 2026

8-K item 2.02, exhibit 99
Latest release Oct 28, 2026 Investor Contact: Media Contact:
Releases kept 12 12 documents, oldest Feb 22, 2024

What BHC's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

What the company says its adjusted numbers leave out:

Adjusted net income (non-GAAP) is Net income (its most directly comparable GAAP financial measure), adjusted for asset impairments, goodwill impairments, restructuring, integration and transformation costs, acquisition-related costs and adjustments (excluding amortization of intangible assets), gain (loss) on extinguishment of debt, separation costs and separation-related costs and other non-GAAP adjustments as these adjustments are described above, and amortization of intangible assets and write down of financing fees as described below: release Oct 28, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Oct 28, 2026 · EX-99.1

Investor Contact: Media Contact:

Open on SEC

Investor Contact: Media Contact: Garen Sarafian Alexis Navratil [email protected] [email protected] (877) 281-6642 (toll free) (848) 264-0934

Third Quarter Consolidated Revenues of $2.94 billion, up 10% on a Reported basis and 8% on an Organic

GAAP Net Income Attributable to Bausch Health of $436 million and GAAP Net Income of $446 million

GAAP Earnings per Diluted Share Attributable to Bausch Health of $1.15 compared to $0.48 in the prior year period; Adjusted Earnings per Diluted Share

of $1,305 million, up 32% over the prior year period BAUSCH HEALTH EXCLUDING BAUSCH + LOMB THIRD QUARTER 2026 RESULTS

Delivered fourteenth consecutive quarter of year-over-year Revenue and Adjusted EBITDA

Generated $581 million in Cash Provided by Operating Activities and $539 million in Adjusted Cash Flows from Operations

LAVAL, QC, October 28, 2026 – Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2026 financial results and other key updates from the quarter.

"Bausch Health, excluding Bausch + Lomb, delivered another solid quarter, marking fourteen consecutive quarters of year-over-year Revenue and Adjusted EBITDA growth. We also achieved an important milestone, with quarterly Adjusted EBITDA, excluding Bausch + Lomb, exceeding $1 billion for the first time. Our performance reflects disciplined execution across the portfolio, with healthy cash generation supporting more than $500 million of net debt reduction during the quarter. These results give us confidence to again raise our full year 2026 guidance. We remain focused on operational excellence, sustainable growth, and long-term value creation," said Thomas J. Appio, Chief Executive Officer, Bausch Health.

The Company also announced that its Board of Directors has authorized a $50 million share repurchase program, with the primary objective of offsetting dilution associated with the anticipated vesting of management equity awards in 2027.

Total consolidated reported revenues were $2.94 billion for the third quarter of 2026, compared with $2.68 billion in the third quarter of 2025, an increase of $260 million, or 10%. Excluding the impact of acquisitions of $37 million and divestitures and discontinuations of $11 million, revenue increased 8% on an organic 1 basis compared with the third quarter of 2025. The net impact of foreign exchange was de minimis in the quarter.

1 This is a non-GAAP measure or a non-GAAP ratio. For further information on non-GAAP measures and non-GAAP ratios, please refer to the "Non-GAAP Information" section of this news release. Please also refer to tables at the end of this news release for a reconciliation of this and other non-GAAP measures and ratios to the most directly comparable GAAP measure. 1 | Page

Salix segment reported revenues were $831 million for the third quarter of 2026, compared with $716 million for the third quarter of 2025, an increase of $115 million, or 16%. Segment revenues increased 14% on an organic 1 basis compared with the third quarter of 2025. Xifaxan® was the primary contributor to growth, with 16% revenue growth in the third quarter of 2026.

International segment reported revenues were $299 million for the third quarter of 2026, compared with $286 million for the third quarter of 2025, an increase of $13 million, or 5%. Excluding the impact of foreign exchange of $4 million, segment revenues grew 4% on an organic 1 basis compared with the third quarter of 2025, led by Canada.

Solta Medical segment reported revenues were $165 million for the third quarter of 2026, compared with $140 million in the third quarter of 2025, an increase of $25 million, or 18% aided by the acquisition of our full service distributor in China. Excluding a $2 million favorable impact from foreign exchange and acquisitions of $29 million, segment revenues decreased by 4% on an organic 1 basis compared with the third quarter of 2025 with the Asia Pacific region decreasing modestly.

Diversified segment reported revenues were $271 million for the third quarter of 2026, compared with $258 million for the third quarter of 2025, an increase of $13 million, or 5%. Segment revenues increased 5% on an organic 1 basis compared with the third quarter of 2025. The increase in organic 1 revenue was primarily driven by double-digit growth in Dermatology.

Bausch + Lomb segment reported revenues were $1.38 billion for the third quarter of 2026, compared with $1.28 billion for the third quarter of 2025, an increase of $94 million, or 7%. Excluding the impact of foreign exchange of $6 million, acquisitions of $8 million and divestitures and discontinuations of $2 million, segment revenues increased 7% on an organic 1 basis compared with the third quarter of 2025. 2 | Page

Consolidated operating income was $983 million for the third quarter of 2026, compared with consolidated operating income of $619 million for the third quarter of 2025, an increase of $364 million.

Consolidated net income attributable to Bausch Health for the third quarter of 2026 was $436 million, compared with consolidated net income attributable to Bausch Health of $179 million for the third quarter of 2025.

Consolidated adjusted net income attributable to Bausch Health 1 for the third quarter of 2026 was $673 million, compared with $434 million for the third quarter of 2025, an increase of $239 million.

Consolidated earnings per share attributable to Bausch Health for the third quarter of 2026 was $1.15 on a diluted basis, compared with consolidated earnings per share of $0.48 on a diluted basis for the third quarter of 2025.

Consolidated adjusted earnings per share attributable to Bausch Health 1 for the third quarter of 2026 was $1.77, compared with $1.16 for the third quarter of 2025.

Consolidated adjusted EBITDA attributable to Bausch Health 1 was $1,305 million for the third quarter of 2026, compared with $986 million for the third quarter of 2025, an increase of $319 million.

The Company generated $813 million of cash from operating activities in the third quarter of 2026, an increase of 101% versus $405 million in the third quarter of 2025.

As of September 30, 2026, Bausch Health reported consolidated cash and cash equivalents of $2,485 million, up from $1,309 million as of December 31, 2025. The Company remains focused on strengthening its balance sheet and delivering value to all stakeholders.

The Company exits the third quarter of 2026 with strong financial momentum, with revenue and earnings growth across multiple segments. Upon the successful completion of major refinancing initiatives in the prior twelve-month period, the Company materially improved its debt maturity profile. The Company remains committed to evaluating all options for unlocking shareholder value, including maximizing the value of our Bausch Health and Bausch + Lomb assets. 3 | Page

The Company updated its Consolidated full year Revenue and Adjusted EBITDA 1 guidance for 2026.

Bausch Health (excluding Bausch + Lomb) is raising its full year Revenue, Adjusted EBITDA 1 , and Adjusted Cash Flows from Operations 1 guidance, which includes the currently estimated impact of applicable tariffs for the calendar year as of the date of this release.

Other than with respect to GAAP revenues, the Company only provides guidance on a non-GAAP basis. The Company does not provide a reconciliation of forward- looking Adjusted EBITDA 1 to GAAP net income (loss) or forward-looking Adjusted Cash Flows from Operations 1 to GAAP cash provided by operating activities, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Because deductions (such as restructuring, gain or loss on extinguishment of debt and litigation and other matters) used to calculate projected net income (loss) and payments (such as payments of legal settlements, transformation costs, separation costs and separation-related costs, interest charged against premium, financing fees paid in connection with the debt refinancing transactions and acquired IPR&D expense) used to calculate Adjusted Cash Flows from Operations 1 vary dramatically based on actual events, the Company is not able to forecast on a GAAP basis with reasonable certainty all adjustments needed in order to provide a GAAP calculation of projected net income (loss) or cash provided by operating activities at this time. The amount of these adjustments may be material and, therefore, could result in projected GAAP net income (loss) being materially less than projected Adjusted EBITDA 1 . These statements represent forward- looking information and may represent a financial outlook, and actual results may vary. Please see the risks and assumptions referred to in the “Forward- looking Statements” section of this news release. The guidance in this news release is only effective as of the date it is given and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance. The rapid recent developments in the evolving landscape of tariffs and responses have resulted in uncertainty regarding these measures and the effects they may have. We continue to assess the direct and indirect impacts on our businesses of such tariffs, including retaliatory tariffs and other trade protectionist measures as the situation develops, and there can be no assurance that such impacts will not be adverse. 4 | Page

A replay of the conference call will be available on the investor relations website.

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn .

This news release contains forward-looking information and statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws (collectively, “forward-looking statements”), including, but not limited to, statements relating to the Company’s: future prospects and performance, financial guidance, research and development efforts and anticipated timing or results thereof, proposed plan to separate its eye health business, including the timing thereof, management of its balance sheet, generation of cash, ability to launch and commercialize new products, including the timing of regulatory processes with respect to the Company’s product pipeline, ability to enforce and defend its Xifaxan® intellectual property rights, ability to execute its growth strategies and strategic priorities generally, and other corporate and strategic transactions. Forward-looking statements may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and positive and negative variations or similar expressions, and phrases or statements that certain actions, events or results may, could, should or will be achieved, received or taken, or will occur or result, and similar such expressions also identify forward-looking information. These forward-looking statements, including the full year guidance, are based upon the current expectations and beliefs of management. The Company’s 2026 financial outlook and full year guidance are included to provide further information about management’s expectations about the Company’s future business operations, activities and results and may not be appropriate for other purposes.

These forward-looking statements are subject to certain factors, risks and uncertainties that could cause actual results to differ materially from those described in these forward-looking statements. These factors, risks and uncertainties include, but are not limited to: our ability to execute our business strategy, business plans and operational efficiency initiatives; demand for, competitive positioning of and pricing for our current and anticipated products and our ability to achieve expected revenues, margins and expense levels; the successful development, regulatory approval, manufacture and timing of launches and commercialization of pipeline and other products; the completion, timing, integration and expected benefits of completed and pending acquisitions and other strategic transactions (including the potential separation of our eye health business consisting of our Bausch + Lomb global Vision Care, Surgical and Pharmaceuticals businesses) on anticipated terms, timing and costs; the scope, duration and financial and operational impact of product quality matters 5 | Page

and manufacturing facility compliance and certification matters; the continued availability and performance of key third-party distribution, fulfillment and other arrangements and the stability of global supply chains; the continuation of patent protection and regulatory exclusivity for key products; the expected impacts of the Inflation Reduction Act, and the impact of the negotiated prices for Xifaxan®, expected to become effective in 2027, under certain programs of the Centers for Medicare & Medicaid Services, and other healthcare reform measures and our ability to mitigate the impact thereof; our ability to generate cash flows and access liquidity to meet working capital needs, satisfy debt maturities as they become due, reduce debt levels and comply with financial and other covenants under our financing arrangements; the expected scope and impact of tariffs, counter-tariffs and other trade restrictions and the effectiveness of mitigation actions and the Company's ability to recover any tariffs that are eligible for refund claims; macroeconomic and geopolitical conditions (including inflation, recessionary pressures, foreign currency exchange rates and interest rates), changes in tax laws and related guidance (including legislation referred to as the One Big Beautiful Bill Act and Organisation for Economic Co-operation and Development related measures); the expected outcomes of litigation, subpoenas, investigations, inspections, reviews, audits, regulatory proceedings and other contingencies; the recent changes to the composition of the Bausch + Lomb board of directors and executive leadership team including the appointment of Bausch Health’s Chief Executive Officer, as Chairman of the board of directors and interim Chief Executive Officer of Bausch + Lomb while concurrently serving as Bausch Health’s Chief Executive Officer; and other factors, risks and uncertainties discussed in the Company’s most recent annual and quarterly reports and detailed from time to time in the Company’s other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors, risks and uncertainties are incorporated herein by reference.

We caution that, as it is not possible to predict or identify all relevant factors that may impact forward-looking statements, the factors referred to above are not exhaustive and should not be considered a complete statement of all potential risks and uncertainties. When relying on our forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the aforementioned factors and other uncertainties and potential events. These forward-looking statements speak only as of the date made. Bausch Health undertakes no obligation to update any of these forward- looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, except as required by law.

To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures and non-GAAP ratios to provide supplemental information to readers. Management uses these non-GAAP measures and ratios as key metrics in the evaluation of the Company’s performance and the consolidated financial results and, in part, in the determination of cash bonuses for its executive officers. The Company believes these non-GAAP measures and ratios are useful to investors in their assessment of our operating performance and the valuation of the Company. In addition, these non-GAAP measures and ratios address questions the Company routinely receives from analysts and investors, and in order to assure that all investors have access to similar data, the Company has determined that it is appropriate to make this data available to all investors.

However, these measures and ratios are not prepared in accordance with GAAP nor do they have any standardized meaning under GAAP. In addition, other companies may use similarly titled non-GAAP financial measures and ratios that are calculated differently from the way we calculate such measures and ratios. Accordingly, our non-GAAP financial measures and ratios may not be comparable to such similarly titled non-GAAP financial measures and ratios used by other companies. We caution investors not to place undue reliance on such non-GAAP measures and ratios, but instead to consider them with the most directly comparable GAAP measures and ratios. Non-GAAP financial measures and ratios have limitations as analytical tools and should 6 | Page

not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

The reconciliations of these historical non-GAAP financial measures and ratios to the most directly comparable financial measures and ratios calculated and presented in accordance with GAAP are shown in the tables below. However, as indicated above, for guidance purposes, the Company does not provide reconciliations of projected Adjusted EBITDA (non-GAAP) to projected GAAP Net income (loss), due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations. Many of the adjustments and exclusions used to calculate the projected non-GAAP measures may vary significantly based on actual events, so the Company is not able to forecast on a GAAP basis with reasonable certainty all adjustments needed in order to provide a GAAP calculation of these projected amounts. The amounts of these adjustments may be material and, therefore, could result in the GAAP amount being materially different from (including materially less than) the projected non-GAAP measures.

EBITDA (non-GAAP), Adjusted EBITDA (non-GAAP) and Adjusted EBITDA Attributable to Bausch Health (non-GAAP)

EBITDA (non-GAAP) is Net income (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (Benefit from) provision for income taxes, depreciation and amortization. Adjusted EBITDA (non-GAAP) is Net income (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (Benefit from) provision for income taxes, depreciation and amortization, and certain other items described below. Adjusted EBITDA attributable to Bausch Health (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) as defined below.

Management believes that Adjusted EBITDA (non-GAAP) and Adjusted EBITDA attributable to Bausch Health (non-GAAP), along with the GAAP measures used by management, most appropriately reflect how the Company measures the business internally and sets operational goals and incentives. In particular, the Company believes that these metrics focus management on the Company’s underlying operational results and business performance. As a result, the Company uses these metrics to assess the financial performance of the Company and to forecast future results as part of its guidance. Management believes these metrics are a useful measure to evaluate current performance. These metrics are intended to show our unleveraged, pre-tax operating results and therefore reflect our financial performance based on operational factors. In addition, cash bonuses for the Company’s executive officers and other key employees are based, in part, on the achievement of certain Adjusted EBITDA (non-GAAP) targets.

Adjusted EBITDA (non-GAAP) is Net income (loss) (its most directly comparable GAAP financial measure) adjusted for interest, income taxes, depreciation and amortization and the following items:

• Restructuring, integration and transformation costs : The Company has incurred restructuring costs as it implemented certain strategies, which involved, among other things, improvements to its infrastructure and operations, internal reorganizations and impacts from the divestiture of assets and businesses. With regard to infrastructure and operational improvements which the Company has taken to improve efficiencies in the businesses and facilities, these tend to be costs intended to right size the business or organization that fluctuate significantly between periods in amount, size and timing, depending on the improvement project, reorganization or transaction. Additionally, the Company is launching certain transformation initiatives that will result in certain changes to and investment in its organizational structure and operations. These transformation initiatives arise outside of the ordinary course of continuing operations and, as is the case with the Company’s restructuring efforts, costs associated with these transformation initiatives are expected to fluctuate between periods in amount, 7 | Page

size and timing. These out-of-the-ordinary-course charges include third-party advisory costs, as well as certain severance-related costs. Investors should understand that the outcome of these transformation initiatives may result in future restructuring actions and certain of these charges could recur. The Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company’s operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.

• Asset impairments : The Company has excluded the impact of impairments of finite-lived and indefinite-lived intangible assets, as well as impairments of assets held for sale, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions and divestitures. The Company believes that the adjustments of these items correlate with the sustainability of the Company’s operating performance. Although the Company excludes impairments of intangible assets and assets held for sale from measuring the performance of the Company and the business, the Company believes that it is important for investors to understand that intangible assets contribute to revenue generation.

• Goodwill impairments: The Company excludes the impact of goodwill impairments. When the Company has made acquisitions where the consideration paid was in excess of the fair value of the net assets acquired, the remaining purchase price is recorded as goodwill. For assets that we developed ourselves, no goodwill is recorded. Goodwill is not amortized but is tested for impairment. The amount of goodwill impairment is measured as the excess of a reporting unit’s carrying value over its fair value. Management excludes these charges in measuring the performance of the Company and the business.

• Share-based compensation : The Company has excluded costs relating to share- based compensation. The Company believes that the exclusion of share-based compensation expense assists investors in the comparisons of operating results to peer companies. Share-based compensation expense can vary significantly based on the timing, size and nature of awards granted.

• Acquisition-related costs and adjustments (excluding amortization of intangible assets) : The Company has excluded the impact of acquisition-related costs and fair value inventory step-up resulting from acquisitions as the amounts and frequency of such costs and adjustments are not consistent and are significantly impacted by the timing and size of its acquisitions. In addition, the Company excludes acquisition-related contingent consideration non-cash adjustments due to the inherent uncertainty and volatility associated with such amounts based on changes in assumptions with respect to fair value estimates, and the amount and frequency of such adjustments are not consistent and are significantly impacted by the timing and size of the Company’s acquisitions, as well as the nature of the agreed-upon consideration.

• Loss (gain) on extinguishment of debt : The Company has excluded loss (gain) on extinguishment of debt as this represents a gain or loss from refinancing our existing debt and is not a reflection of our operations for the period. Further, the amount and frequency of such amounts are not consistent and are significantly impacted by the timing and size of debt financing transactions and other factors in the debt market out of management’s control.

• Separation costs and separation-related costs: The Company has excluded certain costs incurred in connection with activities regarding the separation of the eye-health business. Separation costs are incremental costs directly related to effectuating the separation of the eye-health business, and include, but are not limited to, legal, audit and advisory fees. Separation-related costs are incremental costs indirectly related to the separation of the eye-health business and include, but are not limited to, rebranding costs and costs associated with facility relocation and/or modification. As these costs arise from events outside of the ordinary course of continuing operations, the Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company’s operating performance, allow for a comparison of the financial results to historical 8 | Page

operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.

• Other adjustments : The Company has excluded certain other amounts, including legal and other professional fees incurred in connection with legal and governmental proceedings, investigations and information requests regarding certain of our legacy distribution, marketing, pricing, disclosure and accounting practices, litigation and other matters, and net (gain) loss on sale of assets or other disposition of assets. Given the unique nature of the matters relating to these costs, the Company believes these items are not normal operating expenses. For example, legal settlements and judgments vary significantly, in their nature, size and frequency, and, due to this volatility, the Company believes the costs associated with legal settlements and judgments are not normal operating expenses. In addition, as opposed to more ordinary course matters, the Company considers that each of the recent proceedings, investigations and information requests, given their nature and frequency, are outside of the ordinary course and relate to unique circumstances. The Company has also excluded IT infrastructure investments that are the result of other, non-comparable events to measure operating performance. These events arise outside of the ordinary course of continuing operations. The Company has also excluded certain other costs, including professional fees associated with contemplated, but not completed, strategic transactions. The Company excluded these costs as the consideration of such matters are outside of the ordinary course of continuing operations and are infrequent in nature. The Company believes that the exclusion of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the Company from period to period and, therefore, provides useful supplemental information to investors. However, investors should understand that many of these costs could recur and that companies in our industry often face litigation.

Adjusted EBITDA attributable to Bausch Health (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to noncontrolling interest (non-GAAP). Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) is Net income attributable to noncontrolling interest (its most directly comparable GAAP financial measure) adjusted for the portion of the adjustments described above attributable to noncontrolling interest.

Adjusted Net Income (non-GAAP) and Adjusted Net Income attributable to Bausch Health (non-GAAP)

Adjusted net income (non-GAAP) is Net income (its most directly comparable GAAP financial measure), adjusted for asset impairments, goodwill impairments, restructuring, integration and transformation costs, acquisition-related costs and adjustments (excluding amortization of intangible assets), gain (loss) on extinguishment of debt, separation costs and separation-related costs and other non-GAAP adjustments as these adjustments are described above, and amortization of intangible assets and write down of financing fees as described below:

• Amortization of intangible assets : The Company has excluded the impact of amortization of intangible assets, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions. The Company believes that the adjustments of these items correlate with the sustainability of the Company’s operating performance. Although the Company excludes the amortization of intangible assets from its non-GAAP expenses, the Company believes that it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in the amortization of additional intangible assets.

• Write down of financing fees: In addition to excluding Loss (gain) on extinguishment of debt, the Company has excluded the impact of the write down of financing fees from Adjusted net income (non-GAAP). The amount and frequency of such amounts are not consistent and are significantly impacted 9 | Page

by the timing and size of debt financing transactions and other factors in the debt market out of management’s control. In addition, the Company excluded these costs as they are outside of the ordinary course of continuing operations and are infrequent in nature. The Company believes that the exclusion of such out- of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the Company from period to period and, therefore, provides useful supplemental information to investors.

Adjusted net income attributable to Bausch Health (non-GAAP) is Adjusted net income (non-GAAP) further adjusted to exclude the Adjusted net income attributable to noncontrolling interest (non-GAAP). Adjusted net income attributable to noncontrolling interest (non-GAAP) is Net income attributable to noncontrolling interest (its most directly comparable GAAP financial measure) adjusted for the portion of the adjustments described above attributable to noncontrolling interest.

Historically, management has used Adjusted net income (loss) (non-GAAP) for strategic decision making, forecasting future results and evaluating current performance. This non-GAAP measure excludes the impact of certain items (as described above) that may obscure trends in the Company’s underlying performance. By disclosing this non-GAAP measure, it is management’s intention to provide investors with a meaningful, supplemental comparison of the Company’s operating results and trends for the periods presented. Management believes that this measure is also useful to investors as such measure allows investors to evaluate the Company’s performance using the same tools that management uses to evaluate past performance and prospects for future performance. Accordingly, the Company believes that Adjusted net income (non-GAAP) is useful to investors in their assessment of the Company’s operating performance. It is also noted that, in recent periods, our GAAP Net income (loss) was significantly lower than our Adjusted net income (non-GAAP).

Adjusted earnings per share (non-GAAP) is calculated as Basic and Diluted loss per share attributable to Bausch Health (its most directly comparable GAAP financial measure), adjusted for the non-GAAP adjustments to reconcile Net income (loss) attributable to Bausch Health to Adjusted income attributable to Bausch Health (non-GAAP) and the diluted effect of stock options and restricted stock units excluded in the determination of Basic and Diluted loss per share attributable to Bausch Health during the period as the effect of including them would have been antidilutive. Management believes this non-GAAP measure excludes certain factors that could distort the visibility of the Company’s underlying performance per share and offers investors a clearer, supplemental view of the Company’s performance and trends over the reported periods. As a result, the Company considers Adjusted earnings per share (non-GAAP) to be beneficial for investors evaluating the Company’s operating results, overall valuation, and potential return on investment. Management notes that for the periods presented, the Company’s GAAP EPS was notably lower than its Adjusted earnings per share (non-GAAP).

Organic revenue (non-GAAP) and Change in organic revenue (non-GAAP), are defined as GAAP Revenue and change in GAAP Revenue (the most directly comparable GAAP financial measures), adjusted for changes in foreign currency exchange rates (if applicable) and excluding the impact of recent acquisitions, divestitures and discontinuations, as defined below.

Organic revenue (non-GAAP) is impacted by changes in product volumes and price. The price component is made up of two key drivers: (i) changes in product gross selling price and (ii) changes in sales deductions. The Company uses organic revenue (non-GAAP) and change in organic revenue (non-GAAP) to assess performance of its reportable segments, and the Company in total. The Company believes that providing these non-GAAP measures is useful to investors as they provide a supplemental period-to-period comparison. 10 | Page

The adjustments to GAAP Revenue to determine Organic Revenue (non-GAAP) and Change in Organic Revenue (non-GAAP) are as follows:

• Foreign currency exchange rates: Although changes in foreign currency exchange rates are part of our business, they are not within management’s control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the business. The impact of changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

• Acquisitions, divestitures and discontinuations: In order to present period- over-period organic revenue (non-GAAP) growth/change on a comparable basis, revenues associated with acquisitions, divestitures and discontinuations are adjusted to include only revenues from those businesses and assets owned during both periods. Accordingly, organic revenue and change in organic revenue exclude from the current period, revenues attributable to each acquisition for twelve months subsequent to the day of acquisition, as there are no revenues from those businesses and assets included in the comparable prior period. Organic revenue and change in organic revenue exclude from the prior period, all revenues attributable to each divestiture and discontinuance during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period.

Changes in the relative values of non-U.S. currencies to the U.S. dollar may affect the Company’s financial results and financial position. To assist investors in evaluating the Company’s performance, we have adjusted for the effects of changes in foreign currencies. The impact of changes in foreign currency exchange rates is determined by comparing the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

Please also see the reconciliation tables below for further information as to how these non-GAAP measures and ratios are calculated for the periods presented.

Adjusted cash flows from operations (non-GAAP) is Cash provided by operating activities (its most directly comparable GAAP financial measure) adjusted for: (i) payments of legacy legal settlements, net of insurance recoveries and restitutions, (ii) payments of transformation costs, (iii) payments for separation costs and separation-related costs, (iv) interest payments charged against premium, (v) fees paid in connection with the debt refinancing transactions and (vi) payments of acquired IPR&D.

As these payments arise from events outside of the ordinary course of continuing operations as discussed above, the Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company’s cash from operations, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.

Adjusted EBITDA excluding Bausch + Lomb (non-GAAP) is Adjusted EBITDA (non-GAAP) adjusted to remove Adjusted EBITDA attributable to Bausch + Lomb (non-GAAP). Adjusted EBITDA attributable to Bausch + Lomb (non-GAAP) is Income (loss) before income taxes of our Bausch + Lomb segment (its most directly comparable GAAP financial measure) adjusted for the portion of the Company’s interest expense, depreciation, amortization and other adjustments as described above, allocated or attributable to Bausch + Lomb. 11 | Page

Adjusted EBITDA excluding Bausch + Lomb is not intended to be, and may not be, representative of income from continuing operations (for Bausch Health excluding Bausch + Lomb) or from discontinued operations (for Bausch + Lomb) in accordance with GAAP, as: (i) the criteria for that accounting has not been met and (ii) certain cost allocations to Bausch Health excluding Bausch + Lomb and Bausch + Lomb are not in accordance with the criteria for that accounting. As such, Adjusted EBITDA excluding Bausch + Lomb (non-GAAP) as included herein may not be indicative of the results of the operations or Adjusted EBITDA attributable to Bausch Health (non-GAAP) in the future, or if Bausch + Lomb met the criteria to be treated as a discontinued operation during any of the periods presented.

Adjusted Cash Flows from Operations excluding Bausch + Lomb (non-GAAP) is Adjusted Cash Flows from Operations (non-GAAP) adjusted to remove Adjusted Cash Flows from Operations attributable to Bausch + Lomb (non-GAAP). Adjusted Cash Flows from Operations attributable to Bausch + Lomb (non-GAAP) is Cash Flows from Operations of our Bausch + Lomb segment (its most directly comparable GAAP financial measure) adjusted for the portion of the Company’s payment of separation costs, separation-related costs and other adjustments as described above, allocated or attributable to Bausch + Lomb.

Adjusted Cash Flows from Operations excluding Bausch + Lomb is not intended to be, and may not be, representative of Cash Flows from Operations (for Bausch Health excluding Bausch + Lomb) or from discontinued operations (for Bausch + Lomb) in accordance with GAAP, as: (i) the criteria for that accounting has not been met and (ii) certain cost allocations to BHC excluding Bausch + Lomb and Bausch + Lomb are not in accordance with the criteria for that accounting. As such, Adjusted Cash Flows from Operations excluding Bausch + Lomb (non-GAAP) as included herein may not be indicative of the cash flows or Adjusted Cash Flows from Operations attributable to Bausch Health (non-GAAP) in the future, or if Bausch + Lomb met the criteria to be treated as a discontinued operation during any of the periods presented.

Management believes that Adjusted EBITDA excluding Bausch + Lomb (non-GAAP), Adjusted Cash Flows from Operations (non-GAAP) and Adjusted Cash Flows from Operations excluding Bausch + Lomb (non-GAAP), along with the GAAP and other non-GAAP measures used by management, most appropriately reflects how the Company measures the business internally and sets operational goals and incentives. In particular, the Company believes that these metrics focus management on the Company's underlying operational results and business performance. As a result, the Company uses these metrics to assess the actual financial performance of the Company and to forecast future results as part of its guidance. Management believes these metrics are a useful measure to evaluate current performance. These metrics are intended to show our unleveraged, pre-tax operating results and therefore reflect our financial performance based on operational factors. In addition, cash bonuses for the Company's executive officers and other key employees are based, in part, on the achievement of certain Adjusted EBITDA (non-GAAP) and Adjusted Cash Flows from Operations (non- GAAP) targets.

Net Debt (non-GAAP) is long-term debt (its most directly comparable GAAP financial measure) adjusted for premiums, discount and issuance costs less unrestricted cash and cash equivalents.

Net Debt excluding Bausch + Lomb (non-GAAP) is Net Debt (non-GAAP) adjusted to remove Net Debt attributable to Bausch + Lomb (non-GAAP). Net Debt attributable to Bausch + Lomb (non-GAAP) is long-term debt of our Bausch + Lomb segment (its most directly comparable GAAP financial measure) adjusted for the portion of the Company’s premiums, discount and issuance costs less unrestricted cash and cash equivalents allocated or attributable to Bausch + Lomb. 12 | Page

Management believes Net Debt (non-GAAP) and Net Debt excluding Bausch + Lomb (non-GAAP) provides investors with useful information regarding the Company's overall leverage position and its ability to service its outstanding debt obligations. 13 | Page

(a) The components of and further details respecting each of these non-GAAP adjustments and the financial statement line item to which each component relates can be found on Table 2a.

(b) This is a non-GAAP measure. For further information on non-GAAP measures and non-GAAP ratios, please refer to the “Non-GAAP Information” section of this news release.

(c) Adjusted earnings per share attributable to Bausch Health Companies Inc. is calculated using diluted weighted average common shares of 379.3 million which includes the diluted effect of stock options and restricted stock units of 4.8 million (the “Dilutive Shares”) for the nine months ended September 30, 2026. The Dilutive Shares were not included in the determination of basic and diluted loss per share attributable to Bausch Health Companies Inc. as the effect of including them would have been antidilutive. 15 | Page

(a) Represents the three components of the non-GAAP adjustment of “Acquisition- related costs and adjustments (excluding amortization of intangible assets)” (see Table 2).

(b) Represents the four components of the non-GAAP adjustment of “Other” (see Table 2).

(c) Represents the one component of the non-GAAP adjustment of “Separation costs and separation-related costs” (see Table 2).

(d) Represents the two components of the non-GAAP adjustment of “Restructuring, integration and transformation costs” (see table 2).

(e) Represents the sole component of the non-GAAP adjustment of “Amortization of intangible assets” (see Table 2).

(f) Represents the sole component of the non-GAAP adjustment of “Goodwill impairments” (see Table 2).

(g) Represents the sole component of the non-GAAP adjustment of “Litigation and other matters, net of insurance recoveries and restitutions” (see Table 2).

(h) Represents the sole component of the non-GAAP adjustment of “Gain on sale of assets, net” (see Table 2).

(i) Represents the sole component of the non-GAAP adjustment of “Asset impairments” (see Table 2).

(j) Represents the two components of the non-GAAP adjustment of “Gain (loss) on extinguishment of debt and write-down of financing fees” (see Table 2).

(k) Represents the sole component of the non-GAAP adjustment of “Tax effect of non-GAAP adjustments” (see Table 2).

(l) Represents the portion of the non-GAAP adjustments attributable to noncontrolling interest (see Table 2). 17 | Page

(a) This is a non-GAAP measure. For further information on non-GAAP measures and non-GAAP ratios, please refer to the “Non-GAAP Information” section of this news release.

(b) Includes the impact of Acquired IPR&D charges of $0 and $81 million for the three months ended September 30, 2026 and 2025, respectively, and $16 million and $110 million for the nine months ended September 30, 2026 and 2025, respectively.

(c) Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) is Net (income) loss attributable to noncontrolling interest adjusted for the noncontrolling interest portion of the adjustments above as follows:

(d) Includes the impact of Acquired IPR&D charges net of noncontrolling interest (non-GAAP) of $0 and $81 million for the three months ended September 30, 2026 and 2025, respectively and $14 million and $106 million for the nine months ended September 30, 2026 and 2025, respectively. 18 | Page

(a) The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

(b) This is a non-GAAP measure. For further information on non-GAAP measures and non-GAAP ratios, please refer to the “Non-GAAP Information” section of this news release. 19 | Page

(a) The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

(b) This is a non-GAAP measure. For further information on non-GAAP measures and non-GAAP ratios, please refer to the “Non-GAAP Information” section of this news release. 20 | Page

( a) Payments of legacy legal settlements, net of insurance recoveries and restitutions.

(b) This is a non-GAAP measure. For further information on non-GAAP measures and non-GAAP ratios, please refer to the “Non-GAAP Information” section of this news release. 21 | Page

Bausch Health Three Companies Months Inc. Ended Other September Financial 30, 2026 Bausch Informat… Bausch Health (unaudit… Health (excl. (in Companies Bausch + B+L)(a), Table 4 millions) Inc. Lomb(a) (b) (continu… ────────────────────────────────────────────────────────────────────────────── Cash provided by $ 813 $ 233 $ 581 operating activiti… Payments of 12 11 1 transfor… costs Interest payments charged -44 — -44 against debt premium Payments of 1 — 1 acquired IPR&D Adjusted cash flows $ 782 $ 244 $ 539 from operatio…

(a) This is a non-GAAP measure. Management considers the presentation of Adjusted cash flows from operations for Bausch Health (excl. B+L) (non-GAAP) to be meaningful information and utilizes it in decision making and for compensation purposes. Adjusted cash flows from operations for Bausch Health (excl. B+L) (non-GAAP) is not intended to be representative of GAAP operating activities and Adjusted cash flows from operations for B+L (non-GAAP) is not intended to be representative of discontinued operations as the criteria for that accounting has not been met. As such, Adjusted cash flows from operations excluding B+L (non-GAAP) as included herein may not be indicative of the results of the operations or Adjusted cash flows from operations attributable to Bausch Health (non-GAAP) in the future, or if B+L met the criteria to be treated as a discontinued operation during any of the periods presented.

(a) This is a non-GAAP measure. Management considers the presentation of Adjusted EBITDA for Bausch Health (excluding B+L) (non-GAAP) to be meaningful information and utilizes it in decision making and for compensation purposes. Adjusted EBITDA for Bausch Health Excluding B+L (non-GAAP) is not intended to be representative of GAAP continuing operations and Adjusted EBITDA for B+L is not intended to be representative of discontinued operations as the criteria for that accounting has not been met. As such, Adjusted EBITDA for Bausch Health excluding B+L (non-GAAP) as included herein may not be indicative of the results of the operations or Adjusted EBITDA attributable to Bausch Health (non-GAAP) in the future, or if B+L met the criteria to be treated as a discontinued operation during any of the periods presented.

(b) Adjusted EBITDA (non-GAAP) above includes Adjusted EBITDA attributable to noncontrolling interests. For Bausch Health Companies Inc., this amounted to $45 million and $33 million for the three months ended September 30, 2026 and 2025, respectively, which includes $3 million related to B+L in each period. 23 | Page

Full text with the tables
                                                                           
  Investor Contact:             Media Contact:                             
  Garen Sarafian                Alexis Navratil                            
  [email protected]           [email protected]  
  (877) 281-6642 (toll free)    (848) 264-0934                             
                                                                           
      BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE       
                                                                                
  •                                                                             
                                                                                
Third Quarter Consolidated Revenues of $2.94 billion, up 10% on a Reported basis
and 8% on an Organic
                                                                                
  1                                                                             
                                                                                
                                                                                
  basis over the prior year period                                              
                                                                                
                                                                                
  •                                                                             
                                                                                
GAAP Net Income Attributable to Bausch Health of $436 million and GAAP Net
Income of $446 million
                                                                                
  •                                                                             
                                                                                
GAAP Earnings per Diluted Share Attributable to Bausch Health of $1.15 compared
to $0.48 in the prior year period; Adjusted Earnings per Diluted Share
                                                                                
  1                                                                             
                                                                                
                                                                                
  of $1.77                                                                      
                                                                                
compared to $1.16 in the prior year period, an increase of 53%
                                                                                
  •                                                                             
                                                                                
Consolidated Adjusted EBITDA Attributable to Bausch Health
                                                                                
  1                                                                             
                                                                                
of $1,305 million, up 32% over the prior year period
        BAUSCH HEALTH EXCLUDING BAUSCH + LOMB THIRD QUARTER 2026 RESULTS        
                                                                                
  •                                                                             
                                                                                
Delivered fourteenth consecutive quarter of year-over-year Revenue and Adjusted
EBITDA
                                                                                
  1                                                                             
                                                                                
                                                                                
  growth, with 12% Reported and 8% Organic Revenue                              
                                                                                
                                                                                
  1                                                                             
                                                                                
                                                                                
  growth and 32% Adjusted EBITDA                                                
                                                                                
                                                                                
  1                                                                             
                                                                                
                                                                                
  growth                                                                        
                                                                                
                                                                                
  •                                                                             
                                                                                
Net Income increased $205 million over the prior year
                                                                                
  •                                                                             
                                                                                
Generated $581 million in Cash Provided by Operating Activities and $539 million
in Adjusted Cash Flows from Operations
                                                                                
  1                                                                             
                                                                                
                                                                                
  •                                                                             
                                                                                
                                                                                
  Raising full year 2026 Revenue, Adjusted EBITDA                               
                                                                                
                                                                                
  1                                                                             
                                                                                
                                                                                
  , and Adjusted Cash Flows from Operations                                     
                                                                                
                                                                                
  1                                                                             
                                                                                
                                                                                
  guidance                                                                      
                                                                                
LAVAL, QC, October 28, 2026 – Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC)
("Bausch Health" or the "Company" or "we" or "our") today announced its third
quarter 2026 financial results and other key updates from the quarter.

"Bausch Health, excluding Bausch + Lomb, delivered another solid quarter,
marking fourteen consecutive quarters of year-over-year Revenue and Adjusted
EBITDA growth. We also achieved an important milestone, with quarterly Adjusted
EBITDA, excluding Bausch + Lomb, exceeding $1 billion for the first time. Our
performance reflects disciplined execution across the portfolio, with healthy
cash generation supporting more than $500 million of net debt reduction during
the quarter. These results give us confidence to again raise our full year 2026
guidance. We remain focused on operational excellence, sustainable growth, and
long-term value creation," said Thomas J. Appio, Chief Executive Officer, Bausch
Health.

The Company also announced that its Board of Directors has authorized a $50
million share repurchase program, with the primary objective of offsetting
dilution associated with the anticipated vesting of management equity awards in
2027.
                                                                                
  Third Quarter 2026 Revenue Performance                                        
                                                                                
Total consolidated reported revenues were $2.94 billion for the third quarter of
2026, compared with $2.68 billion in the third quarter of 2025, an increase of
$260 million, or 10%. Excluding the impact of acquisitions of $37 million and
divestitures and discontinuations of $11 million, revenue increased 8% on an
organic 1 basis compared with the third quarter of 2025. The net impact of
foreign exchange was de minimis in the quarter.

___________________________________

1 This is a non-GAAP measure or a non-GAAP ratio. For further information on
non-GAAP measures and non-GAAP ratios, please refer to the "Non-GAAP
Information" section of this news release. Please also refer to tables at the
end of this news release for a reconciliation of this and other non-GAAP
measures and ratios to the most directly comparable GAAP measure.
1 | Page

Reported revenues by segment were as follows:
                                                                                
       T…                                               C…           C…         
       M…                      R…                       at           in         
       E…                      C…                       C…           O…         
       S…                                               C…           R…         
       3…                                                                       
  …    2…          2…          A…          P…                                   
  …                                                                             
  …                                                                             
  …          $…          $…          $…        10  %        10  %         8  %  
  …                                                                             
  …                                                                             
  …                                                                             
  …          $…          $…          $…        12  %        11  %         8  %  
  …                                                                             
  …                                                                             
  …          $…          $…          $…        16  %        16  %        14  %  
  …                                                                             
  …          $…          $…          $…         5  %         3  %         4  %  
  …                                                                             
  …                                                                             
  …          $…          $…          $…        18  %        16  %        (4  …  
  …                                                                             
  …          $…          $…          $…         5  %         5  %         5  %  
  …                                                                             
  …                                                                             
  +          $…          $…          $…         7  %         8  %         7  %  
  …                                                                             
  …                                                                             
                                                                                
                                                                                
  Salix Segment                                                                 
                                                                                
Salix segment reported revenues were $831 million for the third quarter of 2026,
compared with $716 million for the third quarter of 2025, an increase of $115
million, or 16%. Segment revenues increased 14% on an organic 1 basis compared
with the third quarter of 2025. Xifaxan® was the primary contributor to growth,
with 16% revenue growth in the third quarter of 2026.
                                                                                
  International Segment                                                         
                                                                                
International segment reported revenues were $299 million for the third quarter
of 2026, compared with $286 million for the third quarter of 2025, an increase
of $13 million, or 5%. Excluding the impact of foreign exchange of $4 million,
segment revenues grew 4% on an organic 1 basis compared with the third quarter
of 2025, led by Canada.
                                                                                
  Solta Medical Segment                                                         
                                                                                
Solta Medical segment reported revenues were $165 million for the third quarter
of 2026, compared with $140 million in the third quarter of 2025, an increase of
$25 million, or 18% aided by the acquisition of our full service distributor in
China. Excluding a $2 million favorable impact from foreign exchange and
acquisitions of $29 million, segment revenues decreased by 4% on an organic 1
basis compared with the third quarter of 2025 with the Asia Pacific region
decreasing modestly.
                                                                                
  Diversified Segment                                                           
                                                                                
Diversified segment reported revenues were $271 million for the third quarter of
2026, compared with $258 million for the third quarter of 2025, an increase of
$13 million, or 5%. Segment revenues increased 5% on an organic 1 basis compared
with the third quarter of 2025. The increase in organic 1 revenue was primarily
driven by double-digit growth in Dermatology.
                                                                                
  Bausch + Lomb Segment                                                         
                                                                                
Bausch + Lomb segment reported revenues were $1.38 billion for the third quarter
of 2026, compared with $1.28 billion for the third quarter of 2025, an increase
of $94 million, or 7%. Excluding the impact of foreign exchange of $6 million,
acquisitions of $8 million and divestitures and discontinuations of $2 million,
segment revenues increased 7% on an organic 1 basis compared with the third
quarter of 2025.
2 | Page
                                                                                
  Consolidated Operating Income                                                 
                                                                                
Consolidated operating income was $983 million for the third quarter of 2026,
compared with consolidated operating income of $619 million for the third
quarter of 2025, an increase of $364 million.

Consolidated Net Income Attributable to Bausch Health

Consolidated net income attributable to Bausch Health for the third quarter of
2026 was $436 million, compared with consolidated net income attributable to
Bausch Health of $179 million for the third quarter of 2025.

Consolidated Adjusted Net Income Attributable to Bausch Health
                                                                                
  1                                                                             
                                                                                
Consolidated adjusted net income attributable to Bausch Health 1 for the third
quarter of 2026 was $673 million, compared with $434 million for the third
quarter of 2025, an increase of $239 million.

Consolidated Earnings Per Share Attributable to Bausch Health

Consolidated earnings per share attributable to Bausch Health for the third
quarter of 2026 was $1.15 on a diluted basis, compared with consolidated
earnings per share of $0.48 on a diluted basis for the third quarter of 2025.
                                                                                
  Consolidated Adjusted Earnings Per Share                                      
                                                                                
                                                                                
  Attributable to Bausch Health                                                 
                                                                                
                                                                                
  1                                                                             
                                                                                
Consolidated adjusted earnings per share attributable to Bausch Health 1 for the
third quarter of 2026 was $1.77, compared with $1.16 for the third quarter of
2025.
                                                                                
  Consolidated Adjusted EBITDA                                                  
                                                                                
                                                                                
  Attributable to Bausch Health                                                 
                                                                                
                                                                                
  1                                                                             
                                                                                
Consolidated adjusted EBITDA attributable to Bausch Health 1 was $1,305 million
for the third quarter of 2026, compared with $986 million for the third quarter
of 2025, an increase of $319 million.

Consolidated Cash Provided by Operating Activities

The Company generated $813 million of cash from operating activities in the
third quarter of 2026, an increase of 101% versus $405 million in the third
quarter of 2025.
                                                                                
  Balance Sheet Highlights                                                      
                                                                                
As of September 30, 2026, Bausch Health reported consolidated cash and cash
equivalents of $2,485 million, up from $1,309 million as of December 31, 2025.
The Company remains focused on strengthening its balance sheet and delivering
value to all stakeholders.
                                                                                
  Focus on Strategic Priorities                                                 
                                                                                
The Company exits the third quarter of 2026 with strong financial momentum, with
revenue and earnings growth across multiple segments. Upon the successful
completion of major refinancing initiatives in the prior twelve-month period,
the Company materially improved its debt maturity profile. The Company remains
committed to evaluating all options for unlocking shareholder value, including
maximizing the value of our Bausch Health and Bausch + Lomb assets.
3 | Page
                                                                                
  2026 Financial Outlook                                                        
                                                                                
The Company updated its Consolidated full year Revenue and Adjusted EBITDA 1
guidance for 2026.

Bausch Health (excluding Bausch + Lomb) is raising its full year Revenue,
Adjusted EBITDA 1 , and Adjusted Cash Flows from Operations 1 guidance, which
includes the currently estimated impact of applicable tariffs for the calendar
year as of the date of this release.
                                                                                
                      Current Guidance                                          
                      (as of October                                            
                      28, 2026)                                                 
 ────────────────────────────────────────────────────────────────────────────── 
                      BHC                   BHC                B+L              
                                            (excl. B+L)                         
  Revenues (in        $10.975 - $11.175     $5.525 - $5.625    $5.450 - $5.550  
  billions)                                                                     
  Revenue growth                            7% - 9%                             
  vs. Prior Year                                                                
  Adjusted                                                                      
  EBITDA1(in          $4.315 - $4.415       $3.225 - $3.275    $1.090 - $1.140  
  billions)                                                                     
  Adj.                                                                          
  EBITDA1growth                             12% - 14%                           
  vs. Prior Year                                                                
  Adjusted Cash                                                                 
  Flows from                                $1.600 - $1.675                     
  Operations1(in                                                                
  billions)                                                                     
                                                                                
Other than with respect to GAAP revenues, the Company only provides guidance on
a non-GAAP basis. The Company does not provide a reconciliation of forward-
looking Adjusted EBITDA 1 to GAAP net income (loss) or forward-looking Adjusted
Cash Flows from Operations 1 to GAAP cash provided by operating activities, due
to the inherent difficulty in forecasting and quantifying certain amounts that
are necessary for such reconciliation. Because deductions (such as
restructuring, gain or loss on extinguishment of debt and litigation and other
matters) used to calculate projected net income (loss) and payments (such as
payments of legal settlements, transformation costs, separation costs and
separation-related costs, interest charged against premium, financing fees paid
in connection with the debt refinancing transactions and acquired IPR&D expense)
used to calculate Adjusted Cash Flows from Operations 1 vary dramatically based
on actual events, the Company is not able to forecast on a GAAP basis with
reasonable certainty all adjustments needed in order to provide a GAAP
calculation of projected net income (loss) or cash provided by operating
activities at this time. The amount of these adjustments may be material and,
therefore, could result in projected GAAP net income (loss) being materially
less than projected Adjusted EBITDA 1 . These statements represent forward-
looking information and may represent a financial outlook, and actual results
may vary. Please see the risks and assumptions referred to in the “Forward-
looking Statements” section of this news release. The guidance in this news
release is only effective as of the date it is given and will not be updated or
affirmed unless and until the Company publicly announces updated or affirmed
guidance. The rapid recent developments in the evolving landscape of tariffs and
responses have resulted in uncertainty regarding these measures and the effects
they may have. We continue to assess the direct and indirect impacts on our
businesses of such tariffs, including retaliatory tariffs and other trade
protectionist measures as the situation develops, and there can be no assurance
that such impacts will not be adverse.
4 | Page
                                                                                
  Conference Call Details                                                       
                                                                                
                                                                   
  Date:       Wednesday, October 28, 2026                          
 ───────────────────────────────────────────────────────────────── 
  Time:       5:00 p.m. EDT                                        
  Webcast:    http://ir.bauschhealth.com/events-and-presentations  
                                                                   
A replay of the conference call will be available on the investor relations
website.
                                                                                
  About Bausch Health                                                           
                                                                                
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified
pharmaceutical company enriching lives through our relentless drive to deliver
better health care outcomes. We develop, manufacture and market a range of
products primarily in gastroenterology, hepatology, neuroscience, dermatology,
dentistry, aesthetics, international pharmaceuticals and eye health, through our
controlling interest in Bausch + Lomb Corporation. Our ambition is to be a
globally integrated healthcare company, trusted and valued by patients, HCPs,
employees and investors. For more information about Bausch Health, visit
www.bauschhealth.com and connect with us on LinkedIn .
                                                                                
  Forward-looking Statements                                                    
                                                                                
This news release contains forward-looking information and statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995 and
applicable Canadian securities laws (collectively, “forward-looking
statements”), including, but not limited to, statements relating to the
Company’s: future prospects and performance, financial guidance, research and
development efforts and anticipated timing or results thereof, proposed plan to
separate its eye health business, including the timing thereof, management of
its balance sheet, generation of cash, ability to launch and commercialize new
products, including the timing of regulatory processes with respect to the
Company’s product pipeline, ability to enforce and defend its Xifaxan®
intellectual property rights, ability to execute its growth strategies and
strategic priorities generally, and other corporate and strategic transactions.
Forward-looking statements may generally be identified by the use of the words
“anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,”
“would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue”
and positive and negative variations or similar expressions, and phrases or
statements that certain actions, events or results may, could, should or will be
achieved, received or taken, or will occur or result, and similar such
expressions also identify forward-looking information. These forward-looking
statements, including the full year guidance, are based upon the current
expectations and beliefs of management. The Company’s 2026 financial outlook and
full year guidance are included to provide further information about
management’s expectations about the Company’s future business operations,
activities and results and may not be appropriate for other purposes.

These forward-looking statements are subject to certain factors, risks and
uncertainties that could cause actual results to differ materially from those
described in these forward-looking statements. These factors, risks and
uncertainties include, but are not limited to: our ability to execute our
business strategy, business plans and operational efficiency initiatives; demand
for, competitive positioning of and pricing for our current and anticipated
products and our ability to achieve expected revenues, margins and expense
levels; the successful development, regulatory approval, manufacture and timing
of launches and commercialization of pipeline and other products; the
completion, timing, integration and expected benefits of completed and pending
acquisitions and other strategic transactions (including the potential
separation of our eye health business consisting of our Bausch + Lomb global
Vision Care, Surgical and Pharmaceuticals businesses) on anticipated terms,
timing and costs; the scope, duration and financial and operational impact of
product quality matters
5 | Page

and manufacturing facility compliance and certification matters; the continued
availability and performance of key third-party distribution, fulfillment and
other arrangements and the stability of global supply chains; the continuation
of patent protection and regulatory exclusivity for key products; the expected
impacts of the Inflation Reduction Act, and the impact of the negotiated prices
for Xifaxan®, expected to become effective in 2027, under certain programs of
the Centers for Medicare & Medicaid Services, and other healthcare reform
measures and our ability to mitigate the impact thereof; our ability to generate
cash flows and access liquidity to meet working capital needs, satisfy debt
maturities as they become due, reduce debt levels and comply with financial and
other covenants under our financing arrangements; the expected scope and impact
of tariffs, counter-tariffs and other trade restrictions and the effectiveness
of mitigation actions and the Company's ability to recover any tariffs that are
eligible for refund claims; macroeconomic and geopolitical conditions (including
inflation, recessionary pressures, foreign currency exchange rates and interest
rates), changes in tax laws and related guidance (including legislation referred
to as the One Big Beautiful Bill Act and Organisation for Economic Co-operation
and Development related measures); the expected outcomes of litigation,
subpoenas, investigations, inspections, reviews, audits, regulatory proceedings
and other contingencies; the recent changes to the composition of the Bausch +
Lomb board of directors and executive leadership team including the appointment
of Bausch Health’s Chief Executive Officer, as Chairman of the board of
directors and interim Chief Executive Officer of Bausch + Lomb while
concurrently serving as Bausch Health’s Chief Executive Officer; and other
factors, risks and uncertainties discussed in the Company’s most recent annual
and quarterly reports and detailed from time to time in the Company’s other
filings with the U.S. Securities and Exchange Commission and the Canadian
Securities Administrators, which factors, risks and uncertainties are
incorporated herein by reference.

We caution that, as it is not possible to predict or identify all relevant
factors that may impact forward-looking statements, the factors referred to
above are not exhaustive and should not be considered a complete statement of
all potential risks and uncertainties. When relying on our forward-looking
statements to make decisions with respect to the Company, investors and others
should carefully consider the aforementioned factors and other uncertainties and
potential events. These forward-looking statements speak only as of the date
made. Bausch Health undertakes no obligation to update any of these forward-
looking statements to reflect events or circumstances after the date of this
news release or to reflect actual outcomes, except as required by law.
                                                                                
  Non-GAAP Information                                                          
                                                                                
To supplement the financial measures prepared in accordance with U.S. generally
accepted accounting principles (GAAP), the Company uses certain non-GAAP
financial measures and non-GAAP ratios to provide supplemental information to
readers. Management uses these non-GAAP measures and ratios as key metrics in
the evaluation of the Company’s performance and the consolidated financial
results and, in part, in the determination of cash bonuses for its executive
officers. The Company believes these non-GAAP measures and ratios are useful to
investors in their assessment of our operating performance and the valuation of
the Company. In addition, these non-GAAP measures and ratios address questions
the Company routinely receives from analysts and investors, and in order to
assure that all investors have access to similar data, the Company has
determined that it is appropriate to make this data available to all investors.

However, these measures and ratios are not prepared in accordance with GAAP nor
do they have any standardized meaning under GAAP. In addition, other companies
may use similarly titled non-GAAP financial measures and ratios that are
calculated differently from the way we calculate such measures and ratios.
Accordingly, our non-GAAP financial measures and ratios may not be comparable to
such similarly titled non-GAAP financial measures and ratios used by other
companies. We caution investors not to place undue reliance on such non-GAAP
measures and ratios, but instead to consider them with the most directly
comparable GAAP measures and ratios. Non-GAAP financial measures and ratios have
limitations as analytical tools and should
6 | Page

not be considered in isolation. They should be considered as a supplement to,
not a substitute for, or superior to, the corresponding measures calculated in
accordance with GAAP.

The reconciliations of these historical non-GAAP financial measures and ratios
to the most directly comparable financial measures and ratios calculated and
presented in accordance with GAAP are shown in the tables below. However, as
indicated above, for guidance purposes, the Company does not provide
reconciliations of projected Adjusted EBITDA (non-GAAP) to projected GAAP Net
income (loss), due to the inherent difficulty in forecasting and quantifying
certain amounts that are necessary for such reconciliations. Many of the
adjustments and exclusions used to calculate the projected non-GAAP measures may
vary significantly based on actual events, so the Company is not able to
forecast on a GAAP basis with reasonable certainty all adjustments needed in
order to provide a GAAP calculation of these projected amounts. The amounts of
these adjustments may be material and, therefore, could result in the GAAP
amount being materially different from (including materially less than) the
projected non-GAAP measures.
                                                                                
   Description of Non-GAAP Financial Measures                                   
                                                                                
EBITDA (non-GAAP), Adjusted EBITDA (non-GAAP) and Adjusted EBITDA Attributable
to Bausch Health (non-GAAP)

EBITDA (non-GAAP) is Net income (loss) (its most directly comparable GAAP
financial measure) adjusted for interest expense, net, (Benefit from) provision
for income taxes, depreciation and amortization. Adjusted EBITDA (non-GAAP) is
Net income (loss) (its most directly comparable GAAP financial measure) adjusted
for interest expense, net, (Benefit from) provision for income taxes,
depreciation and amortization, and certain other items described below. Adjusted
EBITDA attributable to Bausch Health (non-GAAP) is Adjusted EBITDA (non-GAAP)
further adjusted to exclude the Adjusted EBITDA attributable to noncontrolling
interest (non-GAAP) as defined below.

Management believes that Adjusted EBITDA (non-GAAP) and Adjusted EBITDA
attributable to Bausch Health (non-GAAP), along with the GAAP measures used by
management, most appropriately reflect how the Company measures the business
internally and sets operational goals and incentives. In particular, the Company
believes that these metrics focus management on the Company’s underlying
operational results and business performance. As a result, the Company uses
these metrics to assess the financial performance of the Company and to forecast
future results as part of its guidance. Management believes these metrics are a
useful measure to evaluate current performance. These metrics are intended to
show our unleveraged, pre-tax operating results and therefore reflect our
financial performance based on operational factors. In addition, cash bonuses
for the Company’s executive officers and other key employees are based, in part,
on the achievement of certain Adjusted EBITDA (non-GAAP) targets.

Adjusted EBITDA (non-GAAP) is Net income (loss) (its most directly comparable
GAAP financial measure) adjusted for interest, income taxes, depreciation and
amortization and the following items:

• Restructuring, integration and transformation costs : The Company has incurred
restructuring costs as it implemented certain strategies, which involved, among
other things, improvements to its infrastructure and operations, internal
reorganizations and impacts from the divestiture of assets and businesses. With
regard to infrastructure and operational improvements which the Company has
taken to improve efficiencies in the businesses and facilities, these tend to be
costs intended to right size the business or organization that fluctuate
significantly between periods in amount, size and timing, depending on the
improvement project, reorganization or transaction. Additionally, the Company is
launching certain transformation initiatives that will result in certain changes
to and investment in its organizational structure and operations. These
transformation initiatives arise outside of the ordinary course of continuing
operations and, as is the case with the Company’s restructuring efforts, costs
associated with these transformation initiatives are expected to fluctuate
between periods in amount,
7 | Page

size and timing. These out-of-the-ordinary-course charges include third-party
advisory costs, as well as certain severance-related costs. Investors should
understand that the outcome of these transformation initiatives may result in
future restructuring actions and certain of these charges could recur. The
Company believes that the adjustments of these items provide supplemental
information with regard to the sustainability of the Company’s operating
performance, allow for a comparison of the financial results to historical
operations and forward-looking guidance and, as a result, provide useful
supplemental information to investors.

• Asset impairments : The Company has excluded the impact of impairments of
finite-lived and indefinite-lived intangible assets, as well as impairments of
assets held for sale, as such amounts are inconsistent in amount and frequency
and are significantly impacted by the timing and/or size of acquisitions and
divestitures. The Company believes that the adjustments of these items correlate
with the sustainability of the Company’s operating performance. Although the
Company excludes impairments of intangible assets and assets held for sale from
measuring the performance of the Company and the business, the Company believes
that it is important for investors to understand that intangible assets
contribute to revenue generation.

• Goodwill impairments: The Company excludes the impact of goodwill impairments.
When the Company has made acquisitions where the consideration paid was in
excess of the fair value of the net assets acquired, the remaining purchase
price is recorded as goodwill. For assets that we developed ourselves, no
goodwill is recorded. Goodwill is not amortized but is tested for impairment.
The amount of goodwill impairment is measured as the excess of a reporting
unit’s carrying value over its fair value. Management excludes these charges in
measuring the performance of the Company and the business.

• Share-based compensation : The Company has excluded costs relating to share-
based compensation. The Company believes that the exclusion of share-based
compensation expense assists investors in the comparisons of operating results
to peer companies. Share-based compensation expense can vary significantly based
on the timing, size and nature of awards granted.

• Acquisition-related costs and adjustments (excluding amortization of
intangible assets) : The Company has excluded the impact of acquisition-related
costs and fair value inventory step-up resulting from acquisitions as the
amounts and frequency of such costs and adjustments are not consistent and are
significantly impacted by the timing and size of its acquisitions. In addition,
the Company excludes acquisition-related contingent consideration non-cash
adjustments due to the inherent uncertainty and volatility associated with such
amounts based on changes in assumptions with respect to fair value estimates,
and the amount and frequency of such adjustments are not consistent and are
significantly impacted by the timing and size of the Company’s acquisitions, as
well as the nature of the agreed-upon consideration.

• Loss (gain) on extinguishment of debt : The Company has excluded loss (gain)
on extinguishment of debt as this represents a gain or loss from refinancing our
existing debt and is not a reflection of our operations for the period. Further,
the amount and frequency of such amounts are not consistent and are
significantly impacted by the timing and size of debt financing transactions and
other factors in the debt market out of management’s control.

• Separation costs and separation-related costs: The Company has excluded
certain costs incurred in connection with activities regarding the separation of
the eye-health business. Separation costs are incremental costs directly related
to effectuating the separation of the eye-health business, and include, but are
not limited to, legal, audit and advisory fees. Separation-related costs are
incremental costs indirectly related to the separation of the eye-health
business and include, but are not limited to, rebranding costs and costs
associated with facility relocation and/or modification. As these costs arise
from events outside of the ordinary course of continuing operations, the Company
believes that the adjustments of these items provide supplemental information
with regard to the sustainability of the Company’s operating performance, allow
for a comparison of the financial results to historical
8 | Page

operations and forward-looking guidance and, as a result, provide useful
supplemental information to investors.

• Other adjustments : The Company has excluded certain other amounts, including
legal and other professional fees incurred in connection with legal and
governmental proceedings, investigations and information requests regarding
certain of our legacy distribution, marketing, pricing, disclosure and
accounting practices, litigation and other matters, and net (gain) loss on sale
of assets or other disposition of assets. Given the unique nature of the matters
relating to these costs, the Company believes these items are not normal
operating expenses. For example, legal settlements and judgments vary
significantly, in their nature, size and frequency, and, due to this volatility,
the Company believes the costs associated with legal settlements and judgments
are not normal operating expenses. In addition, as opposed to more ordinary
course matters, the Company considers that each of the recent proceedings,
investigations and information requests, given their nature and frequency, are
outside of the ordinary course and relate to unique circumstances. The Company
has also excluded IT infrastructure investments that are the result of other,
non-comparable events to measure operating performance. These events arise
outside of the ordinary course of continuing operations. The Company has also
excluded certain other costs, including professional fees associated with
contemplated, but not completed, strategic transactions. The Company excluded
these costs as the consideration of such matters are outside of the ordinary
course of continuing operations and are infrequent in nature. The Company
believes that the exclusion of such out-of-the-ordinary-course amounts provides
supplemental information to assist in the comparison of the financial results of
the Company from period to period and, therefore, provides useful supplemental
information to investors. However, investors should understand that many of
these costs could recur and that companies in our industry often face
litigation.

Adjusted EBITDA attributable to Bausch Health (non-GAAP) is Adjusted EBITDA
(non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to
noncontrolling interest (non-GAAP). Adjusted EBITDA attributable to
noncontrolling interest (non-GAAP) is Net income attributable to noncontrolling
interest (its most directly comparable GAAP financial measure) adjusted for the
portion of the adjustments described above attributable to noncontrolling
interest.

Adjusted Net Income (non-GAAP) and Adjusted Net Income attributable to Bausch
Health (non-GAAP)

Adjusted net income (non-GAAP) is Net income (its most directly comparable GAAP
financial measure), adjusted for asset impairments, goodwill impairments,
restructuring, integration and transformation costs, acquisition-related costs
and adjustments (excluding amortization of intangible assets), gain (loss) on
extinguishment of debt, separation costs and separation-related costs and other
non-GAAP adjustments as these adjustments are described above, and amortization
of intangible assets and write down of financing fees as described below:

• Amortization of intangible assets : The Company has excluded the impact of
amortization of intangible assets, as such amounts are inconsistent in amount
and frequency and are significantly impacted by the timing and/or size of
acquisitions. The Company believes that the adjustments of these items correlate
with the sustainability of the Company’s operating performance. Although the
Company excludes the amortization of intangible assets from its non-GAAP
expenses, the Company believes that it is important for investors to understand
that such intangible assets contribute to revenue generation. Amortization of
intangible assets that relate to past acquisitions will recur in future periods
until such intangible assets have been fully amortized. Any future acquisitions
may result in the amortization of additional intangible assets.

• Write down of financing fees: In addition to excluding Loss (gain) on
extinguishment of debt, the Company has excluded the impact of the write down of
financing fees from Adjusted net income (non-GAAP). The amount and frequency of
such amounts are not consistent and are significantly impacted
9 | Page

by the timing and size of debt financing transactions and other factors in the
debt market out of management’s control. In addition, the Company excluded these
costs as they are outside of the ordinary course of continuing operations and
are infrequent in nature. The Company believes that the exclusion of such out-
of-the-ordinary-course amounts provides supplemental information to assist in
the comparison of the financial results of the Company from period to period
and, therefore, provides useful supplemental information to investors.

Adjusted net income attributable to Bausch Health (non-GAAP) is Adjusted net
income (non-GAAP) further adjusted to exclude the Adjusted net income
attributable to noncontrolling interest (non-GAAP). Adjusted net income
attributable to noncontrolling interest (non-GAAP) is Net income attributable to
noncontrolling interest (its most directly comparable GAAP financial measure)
adjusted for the portion of the adjustments described above attributable to
noncontrolling interest.

Historically, management has used Adjusted net income (loss) (non-GAAP) for
strategic decision making, forecasting future results and evaluating current
performance. This non-GAAP measure excludes the impact of certain items (as
described above) that may obscure trends in the Company’s underlying
performance. By disclosing this non-GAAP measure, it is management’s intention
to provide investors with a meaningful, supplemental comparison of the Company’s
operating results and trends for the periods presented. Management believes that
this measure is also useful to investors as such measure allows investors to
evaluate the Company’s performance using the same tools that management uses to
evaluate past performance and prospects for future performance. Accordingly, the
Company believes that Adjusted net income (non-GAAP) is useful to investors in
their assessment of the Company’s operating performance. It is also noted that,
in recent periods, our GAAP Net income (loss) was significantly lower than our
Adjusted net income (non-GAAP).

Adjusted Earnings Per Share (non-GAAP)

Adjusted earnings per share (non-GAAP) is calculated as Basic and Diluted loss
per share attributable to Bausch Health (its most directly comparable GAAP
financial measure), adjusted for the non-GAAP adjustments to reconcile Net
income (loss) attributable to Bausch Health to Adjusted income attributable to
Bausch Health (non-GAAP) and the diluted effect of stock options and restricted
stock units excluded in the determination of Basic and Diluted loss per share
attributable to Bausch Health during the period as the effect of including them
would have been antidilutive. Management believes this non-GAAP measure excludes
certain factors that could distort the visibility of the Company’s underlying
performance per share and offers investors a clearer, supplemental view of the
Company’s performance and trends over the reported periods. As a result, the
Company considers Adjusted earnings per share (non-GAAP) to be beneficial for
investors evaluating the Company’s operating results, overall valuation, and
potential return on investment. Management notes that for the periods presented,
the Company’s GAAP EPS was notably lower than its Adjusted earnings per share
(non-GAAP).

Organic Revenue (non-GAAP) and Change in Organic Revenue (non-GAAP)

Organic revenue (non-GAAP) and Change in organic revenue (non-GAAP), are defined
as GAAP Revenue and change in GAAP Revenue (the most directly comparable GAAP
financial measures), adjusted for changes in foreign currency exchange rates (if
applicable) and excluding the impact of recent acquisitions, divestitures and
discontinuations, as defined below.

Organic revenue (non-GAAP) is impacted by changes in product volumes and price.
The price component is made up of two key drivers: (i) changes in product gross
selling price and (ii) changes in sales deductions. The Company uses organic
revenue (non-GAAP) and change in organic revenue (non-GAAP) to assess
performance of its reportable segments, and the Company in total. The Company
believes that providing these non-GAAP measures is useful to investors as they
provide a supplemental period-to-period comparison.
10 | Page

The adjustments to GAAP Revenue to determine Organic Revenue (non-GAAP) and
Change in Organic Revenue (non-GAAP) are as follows:

• Foreign currency exchange rates: Although changes in foreign currency exchange
rates are part of our business, they are not within management’s control.
Changes in foreign currency exchange rates, however, can mask positive or
negative trends in the business. The impact of changes in foreign currency
exchange rates is determined as the difference in the current period reported
revenues at their current period currency exchange rates and the current period
reported revenues revalued using the monthly average currency exchange rates
during the comparable prior period.

• Acquisitions, divestitures and discontinuations: In order to present period-
over-period organic revenue (non-GAAP) growth/change on a comparable basis,
revenues associated with acquisitions, divestitures and discontinuations are
adjusted to include only revenues from those businesses and assets owned during
both periods. Accordingly, organic revenue and change in organic revenue exclude
from the current period, revenues attributable to each acquisition for twelve
months subsequent to the day of acquisition, as there are no revenues from those
businesses and assets included in the comparable prior period. Organic revenue
and change in organic revenue exclude from the prior period, all revenues
attributable to each divestiture and discontinuance during the twelve months
prior to the day of divestiture or discontinuance, as there are no revenues from
those businesses and assets included in the comparable current period.

Constant Currency

Changes in the relative values of non-U.S. currencies to the U.S. dollar may
affect the Company’s financial results and financial position. To assist
investors in evaluating the Company’s performance, we have adjusted for the
effects of changes in foreign currencies. The impact of changes in foreign
currency exchange rates is determined by comparing the current period reported
revenues at their current period currency exchange rates and the current period
reported revenues revalued using the monthly average currency exchange rates
during the comparable prior period.

Please also see the reconciliation tables below for further information as to
how these non-GAAP measures and ratios are calculated for the periods presented.

Adjusted Cash Flows from Operations (non-GAAP)

Adjusted cash flows from operations (non-GAAP) is Cash provided by operating
activities (its most directly comparable GAAP financial measure) adjusted for:
(i) payments of legacy legal settlements, net of insurance recoveries and
restitutions, (ii) payments of transformation costs, (iii) payments for
separation costs and separation-related costs, (iv) interest payments charged
against premium, (v) fees paid in connection with the debt refinancing
transactions and (vi) payments of acquired IPR&D.

As these payments arise from events outside of the ordinary course of continuing
operations as discussed above, the Company believes that the adjustments of
these items provide supplemental information with regard to the sustainability
of the Company’s cash from operations, allow for a comparison of the financial
results to historical operations and forward-looking guidance and, as a result,
provide useful supplemental information to investors.

Adjusted EBITDA excluding Bausch + Lomb (non-GAAP)

Adjusted EBITDA excluding Bausch + Lomb (non-GAAP) is Adjusted EBITDA (non-GAAP)
adjusted to remove Adjusted EBITDA attributable to Bausch + Lomb (non-GAAP).
Adjusted EBITDA attributable to Bausch + Lomb (non-GAAP) is Income (loss) before
income taxes of our Bausch + Lomb segment (its most directly comparable GAAP
financial measure) adjusted for the portion of the Company’s interest expense,
depreciation, amortization and other adjustments as described above, allocated
or attributable to Bausch + Lomb.
11 | Page

Adjusted EBITDA excluding Bausch + Lomb is not intended to be, and may not be,
representative of income from continuing operations (for Bausch Health excluding
Bausch + Lomb) or from discontinued operations (for Bausch + Lomb) in accordance
with GAAP, as: (i) the criteria for that accounting has not been met and (ii)
certain cost allocations to Bausch Health excluding Bausch + Lomb and Bausch +
Lomb are not in accordance with the criteria for that accounting. As such,
Adjusted EBITDA excluding Bausch + Lomb (non-GAAP) as included herein may not be
indicative of the results of the operations or Adjusted EBITDA attributable to
Bausch Health (non-GAAP) in the future, or if Bausch + Lomb met the criteria to
be treated as a discontinued operation during any of the periods presented.

Adjusted Cash Flows from Operations excluding Bausch + Lomb (non-GAAP)

Adjusted Cash Flows from Operations excluding Bausch + Lomb (non-GAAP) is
Adjusted Cash Flows from Operations (non-GAAP) adjusted to remove Adjusted Cash
Flows from Operations attributable to Bausch + Lomb (non-GAAP). Adjusted Cash
Flows from Operations attributable to Bausch + Lomb (non-GAAP) is Cash Flows
from Operations of our Bausch + Lomb segment (its most directly comparable GAAP
financial measure) adjusted for the portion of the Company’s payment of
separation costs, separation-related costs and other adjustments as described
above, allocated or attributable to Bausch + Lomb.

Adjusted Cash Flows from Operations excluding Bausch + Lomb is not intended to
be, and may not be, representative of Cash Flows from Operations (for Bausch
Health excluding Bausch + Lomb) or from discontinued operations (for Bausch +
Lomb) in accordance with GAAP, as: (i) the criteria for that accounting has not
been met and (ii) certain cost allocations to BHC excluding Bausch + Lomb and
Bausch + Lomb are not in accordance with the criteria for that accounting. As
such, Adjusted Cash Flows from Operations excluding Bausch + Lomb (non-GAAP) as
included herein may not be indicative of the cash flows or Adjusted Cash Flows
from Operations attributable to Bausch Health (non-GAAP) in the future, or if
Bausch + Lomb met the criteria to be treated as a discontinued operation during
any of the periods presented.

Management believes that Adjusted EBITDA excluding Bausch + Lomb (non-GAAP),
Adjusted Cash Flows from Operations (non-GAAP) and Adjusted Cash Flows from
Operations excluding Bausch + Lomb (non-GAAP), along with the GAAP and other
non-GAAP measures used by management, most appropriately reflects how the
Company measures the business internally and sets operational goals and
incentives. In particular, the Company believes that these metrics focus
management on the Company's underlying operational results and business
performance. As a result, the Company uses these metrics to assess the actual
financial performance of the Company and to forecast future results as part of
its guidance. Management believes these metrics are a useful measure to evaluate
current performance. These metrics are intended to show our unleveraged, pre-tax
operating results and therefore reflect our financial performance based on
operational factors. In addition, cash bonuses for the Company's executive
officers and other key employees are based, in part, on the achievement of
certain Adjusted EBITDA (non-GAAP) and Adjusted Cash Flows from Operations (non-
GAAP) targets.

Net Debt (non-GAAP)

Net Debt (non-GAAP) is long-term debt (its most directly comparable GAAP
financial measure) adjusted for premiums, discount and issuance costs less
unrestricted cash and cash equivalents.

Net Debt excluding Bausch + Lomb (non-GAAP)

Net Debt excluding Bausch + Lomb (non-GAAP) is Net Debt (non-GAAP) adjusted to
remove Net Debt attributable to Bausch + Lomb (non-GAAP). Net Debt attributable
to Bausch + Lomb (non-GAAP) is long-term debt of our Bausch + Lomb segment (its
most directly comparable GAAP financial measure) adjusted for the portion of the
Company’s premiums, discount and issuance costs less unrestricted cash and cash
equivalents allocated or attributable to Bausch + Lomb.
12 | Page

Management believes Net Debt (non-GAAP) and Net Debt excluding Bausch + Lomb
(non-GAAP) provides investors with useful information regarding the Company's
overall leverage position and its ability to service its outstanding debt
obligations.
13 | Page
                                                                                
  Baus…                                                                         
  Heal…                                                                         
  Comp…                                                                         
  Inc.                                                                          
  Cond…                                                                         
  Cons…                                                                         
  Stat…                                                                         
  of                                                                            
  Oper…                                                                         
  For                                                                           
  the                                                                           
  Three                                                                         
  and                                                                           
  Nine                                                                          
  Mont…                                                                         
  Ended                                                                         
  Sept…                                                                         
  30,                                                                           
  2026                                                                          
  and                                                                    Table  
  2025                                                                   1      
 ────────────────────────────────────────────────────────────────────────────── 
  (una…                                                                         
           Three                            Nine                                
           Mont…                          Months                                
           Ended                           Ended                                
           Sept…                          Septe…                                
             30,                             30,                                
  (in       2026           2025             2026           2025                 
  mill…                                                                         
  Reve…                                                                         
  Prod…        $  2,912       $  2,657         $  8,237       $   7,388         
  sales                                                                         
  Other              29             24               80              82         
  reve…                                                                         
                  2,941          2,681            8,317           7,470         
  Expe…                                                                         
  Cost                                                                          
  of                                                                            
  goods                                                                         
  sold                                                                          
  (exc…                                                                         
  amor…             721            735            2,195           2,166         
  and                                                                           
  impa…                                                                         
  of                                                                            
  inta…                                                                         
  asse…                                                                         
  Cost                                                                          
  of                 14             15               50              49         
  other                                                                         
  reve…                                                                         
  Sell…                                                                         
  gene…             834            795            2,602           2,556         
  and                                                                           
  admi…                                                                         
  Rese…                                                                         
  and               141            166              477             468         
  deve…                                                                         
  Amor…                                                                         
  of                227            253              693             765         
  inta…                                                                         
  asse…                                                                         
  Good…               —              —            1,426               —         
  impa…                                                                         
  Rest…                                                                         
  inte…                                                                         
  and                10             17               32              49         
  sepa…                                                                         
  costs                                                                         
  Other                                                                         
  expe…              11             81               69              78         
  net                                                                           
                  1,958          2,062            7,544           6,131         
  Oper…             983            619              773           1,339         
  inco…                                                                         
  Inte…              13             15               34              39         
  inco…                                                                         
  Inte…            -398           -412            -1,1…          -1,207         
  expe…                                                                         
  Gain                                                                          
  (los…                                                                         
  on                  —              3               -1             181         
  exti…                                                                         
  of                                                                            
  debt                                                                          
  Fore…                                                                         
  exch…              -1             -7              -19             -41         
  and                                                                           
  other                                                                         
  Inco…                                                                         
  (los…                                                                         
  befo…             597            218             -409             311         
  inco…                                                                         
  taxes                                                                         
  Prov…                                                                         
  for              -151            -37             -316             -88         
  inco…                                                                         
  taxes                                                                         
  Net                                                                           
  inco…             446            181             -725             223         
  (los…                                                                         
  Net                                                                           
  (inc…                                                                         
  loss                                                                          
  attr…             -10             -2               -4              46         
  to                                                                            
  nonc…                                                                         
  inte…                                                                         
  Net                                                                           
  inco…                                                                         
  (los…                                                                         
  attr…                                                                         
  to           $    436       $    179         $   -729       $     269         
  Baus…                                                                         
  Heal…                                                                         
  Comp…                                                                         
  Inc.                                                                          
                                                                                
                                       .                                        
14 | Page
                                                                                
  Baus…                                                                         
  Heal…                                                                         
  Comp…                                                                         
  Inc.                                                                          
  Reco…                                                                         
  of                                                                            
  Net                                                                           
  inco…                                                                         
  (los…                                                                         
  attr…                                                                         
  to                                                                            
  Baus…                                                                         
  Heal…                                                                         
  Comp…                                                                         
  Inc.                                                                          
  to                                                                            
  Adju…                                                                         
  Net                                                                           
  Inco…                                                                         
  Attr…                                                                         
  to                                                                            
  Baus…                                                                         
  Heal…                                                                         
  Comp…                                                                         
  Inc.                                                                          
  (non…                                                                         
  For                                                                           
  the                                                                           
  Three                                                                         
  and                                                                           
  Nine                                                                          
  Mont…                                                                         
  Ended                                                                         
  Sept…                                                                         
  30,                                                                           
  2026                                                                          
  and                                                                   Table   
  2025                                                                  2       
 ────────────────────────────────────────────────────────────────────────────── 
  (una…                                                                         
            Three                           Nine                                
           Months                          Mont…                                
            Ended                          Ended                                
           Septe…                          Sept…                                
              30,                            30,                                
  (in        2026           2025            2026           2025                 
  mill…                                                                         
  Net                                                                           
  inco…                                                                         
  (los…                                                                         
  attr…                                                                         
  to            $    436       $    179        $   -729       $    269          
  Baus…                                                                         
  Heal…                                                                         
  Comp…                                                                         
  Inc.                                                                          
  Non-…                                                                         
  adju…                                                                         
  Amor…                                                                         
  of                 227            253             693            765          
  inta…                                                                         
  asse…                                                                         
  Good…                —              —           1,426              —          
  impa…                                                                         
  Asset                4              1              13              1          
  impa…                                                                         
  Rest…                                                                         
  inte…                                                                         
  and                 16             27              49            108          
  tran…                                                                         
  costs                                                                         
  Acqu…                                                                         
  costs                                                                         
  and                                                                           
  adju…                                                                         
  (exc…               -1            -11              21             -5          
  amor…                                                                         
  of                                                                            
  inta…                                                                         
  asse…                                                                         
  (Gai…                                                                         
  loss                                                                          
  on                                                                            
  exti…                                                                         
  of                                                                            
  debt                 —             -2               9           -128          
  and                                                                           
  write                                                                         
  down                                                                          
  of                                                                            
  fina…                                                                         
  fees                                                                          
  Sepa…                                                                         
  costs                                                                         
  and                  —             -2               2              5          
  sepa…                                                                         
  costs                                                                         
  Gain                                                                          
  on                                                                            
  sale                -2             -6              -5             -6          
  of                                                                            
  asse…                                                                         
  net                                                                           
  Liti…                                                                         
  and                                                                           
  other                                                                         
  matt…                                                                         
  net                 10             35              26             40          
  of                                                                            
  insu…                                                                         
  reco…                                                                         
  and                                                                           
  rest…                                                                         
  Other                5             14              19             74          
  Tax                                                                           
  effe…                                                                         
  of                  -7            -42             -36            -80          
  non-…                                                                         
  adju…                                                                         
  Nonc…                                                                         
  inte…                                                                         
  port…                                                                         
  of                 -15            -12             -43            -54          
  the                                                                           
  non-…                                                                         
  adju…                                                                         
  Adju…                                                                         
  net                                                                           
  inco…                                                                         
  attr…                                                                         
  to            $    673       $    434        $  1,445       $    989          
  Baus…                                                                         
  Heal…                                                                         
  Comp…                                                                         
  Inc.…                                                                         
  Earn…                                                                         
  (los…                                                                         
  per                                                                           
  share                                                                         
  attr…                                                                         
  to                                                                            
  Baus…                                                                         
  Heal…                                                                         
  Comp…                                                                         
  Inc.                                                                          
  Basic         $   1.16       $   0.48        $  -1.95       $   0.73          
  Dilu…         $   1.15       $   0.48        $  -1.95       $   0.72          
  Adju…                                                                         
  earn…                                                                         
  per                                                                           
  share                                                                         
  attr…                                                                         
  to            $   1.77       $   1.16        $   3.81       $   2.64          
  Baus…                                                                         
  Heal…                                                                         
  Comp…                                                                         
  Inc.…                                                                         
  (c)                                                                           
  Weig…                                                                         
  comm…                                                                         
  shar…                                                                         
  Basic            375.5          371.3           374.5          370.6          
  Dilu…            380.7          375.5           379.3          374.1          
                                                                                
(a) The components of and further details respecting each of these non-GAAP
adjustments and the financial statement line item to which each component
relates can be found on Table 2a.

(b) This is a non-GAAP measure. For further information on non-GAAP measures and
non-GAAP ratios, please refer to the “Non-GAAP Information” section of this news
release.

(c) Adjusted earnings per share attributable to Bausch Health Companies Inc. is
calculated using diluted weighted average common shares of 379.3 million which
includes the diluted effect of stock options and restricted stock units of 4.8
million (the “Dilutive Shares”) for the nine months ended September 30, 2026.
The Dilutive Shares were not included in the determination of basic and diluted
loss per share attributable to Bausch Health Companies Inc. as the effect of
including them would have been antidilutive.
15 | Page
                                                                                
  Baus…                                                                         
  Heal…                                                                         
  Comp…                                                                         
  Inc.                                                                          
  Reco…                                                                         
  of                                                                            
  GAAP                                                                          
  to                                                                            
  Non-…                                                                         
  Fina…                                                                         
  Info…                                                                         
  For                                                                           
  the                                                                           
  Three                                                                         
  and                                                                           
  Nine                                                                          
  Mont…                                                                         
  Ended                                                                         
  Sept…                                                                         
  30,                                                                           
  2026                                                                          
  and                                                                   Table   
  2025                                                                  2a      
 ────────────────────────────────────────────────────────────────────────────── 
  (una…                                                                         
            Three                          Nine                                 
           Months                        Months                                 
            Ended                         Ended                                 
           Septe…                        Septe…                                 
              30,                           30,                                 
  (in        2026          2025            2026            2025                 
  mill…                                                                         
  Cost                                                                          
  of                                                                            
  goods                                                                         
  sold                                                                          
  reco…                                                                         
  asse…         $   721       $   735         $   2,195       $  2,166          
  Fair                                                                          
  value                                                                         
  inve…                                                                         
  step…               —           -19                -3            -62          
  resu…                                                                         
  from                                                                          
  acqu…                                                                         
  Adju…                                                                         
  Cost                                                                          
  of                                                                            
  goods                                                                         
  sold                                                                          
  (exc…                                                                         
  amor…         $   721       $   716         $   2,192       $  2,104          
  and                                                                           
  impa…                                                                         
  of                                                                            
  inta…                                                                         
  asse…                                                                         
  (non…                                                                         
  Sell…                                                                         
  gene…                                                                         
  and                                                                           
  admi…                                                                         
  reco…                                                                         
                                                                                
  GAAP                                                                          
  Sell…                                                                         
  gene…         $   834       $   795         $   2,602       $  2,556          
  and                                                                           
  admi…                                                                         
  IT                                                                            
  infr…              -4            -5               -13            -17          
  inve…                                                                         
  Legal                                                                         
  and                                                                           
  other              -1            -5                 —            -19          
  prof…                                                                         
  fees…                                                                         
  Sepa…               —             2                -2             -5          
  cost…                                                                         
  Tran…              -6           -10               -17            -59          
  cost…                                                                         
  Adju…                                                                         
  Sell…                                                                         
  gene…         $   823       $   777         $   2,570       $  2,456          
  and                                                                           
  admi…                                                                         
  (non…                                                                         
  Amor…                                                                         
  of                                                                            
  inta…                                                                         
  asse…                                                                         
  reco…                                                                         
  GAAP                                                                          
  Amor…                                                                         
  of            $   227       $   253         $     693       $    765          
  inta…                                                                         
  asse…                                                                         
  Amor…                                                                         
  of               -227          -253              -693           -765          
  inta…                                                                         
  asse…                                                                         
  Adju…                                                                         
  Amor…                                                                         
  of            $     —       $     —         $       —       $      —          
  inta…                                                                         
  asse…                                                                         
  (non…                                                                         
  Good…                                                                         
  impa…                                                                         
  reco…                                                                         
  GAAP                                                                          
  Good…         $     —       $     —         $   1,426       $      —          
  impa…                                                                         
  Good…               —             —            -1,426              —          
  impa…                                                                         
  Adju…                                                                         
  Good…         $     —       $     —         $       —       $      —          
  impa…                                                                         
  (non…                                                                         
  Rest…                                                                         
  inte…                                                                         
  and                                                                           
  sepa…                                                                         
  costs                                                                         
  reco…                                                                         
                                                                                
  GAAP                                                                          
  Rest…                                                                         
  inte…         $    10       $    17         $      32       $     49          
  and                                                                           
  sepa…                                                                         
  costs                                                                         
  Rest…                                                                         
  and               -10           -17               -32            -49          
  inte…                                                                         
  cost…                                                                         
  Adju…                                                                         
  Rest…                                                                         
  inte…                                                                         
  and           $     —       $     —         $       —       $      —          
  sepa…                                                                         
  costs                                                                         
  (non…                                                                         
  Other                                                                         
  expe…                                                                         
  net                                                                           
  reco…                                                                         
  GAAP                                                                          
  Other         $    11       $    81         $      69       $     78          
  expe…                                                                         
  net                                                                           
  Liti…                                                                         
  and                                                                           
  other                                                                         
  matt…                                                                         
  net               -10           -35               -26            -40          
  of                                                                            
  insu…                                                                         
  reco…                                                                         
  and                                                                           
  rest…                                                                         
  Acqu…                                                                         
  cont…               4            32               -14             72          
  cons…                                                                         
  Gain                                                                          
  on                                                                            
  sale                2             6                 5              6          
  of                                                                            
  asse…                                                                         
  net(…                                                                         
  Acqu…              -3            -2                -4             -5          
  cost…                                                                         
  Asset              -4            -1               -13             -1          
  impa…                                                                         
  Othe…               —             —                -1              —          
  Adju…                                                                         
  Other                                                                         
  expe…         $     —       $    81         $      16       $    110          
  net                                                                           
  (non…                                                                         
                                                                                
16 | Page
                                                                                
  Baus…                                                                         
  Heal…                                                                         
  Comp…                                                                         
  Inc.                                                                          
  Reco…                                                                         
  of                                                                            
  GAAP                                                                          
  to                                                                            
  Non-…                                                                         
  Fina…                                                                         
  Info…                                                                         
  For                                                                           
  the                                                                           
  Three                                                                         
  and                                                                           
  Nine                                                                          
  Mont…                                                                         
  Ended                                                                         
  Sept…                                                                         
  30,                                                                           
  2026                                                                   Table  
  and                                                                    2a     
  2025                                                                   (con…  
 ────────────────────────────────────────────────────────────────────────────── 
  (una…                                                                         
            Three                          Nine                                 
           Months                        Months                                 
            Ended                         Ended                                 
           Septe…                        Septe…                                 
              30,                           30,                                 
  (in        2026          2025            2026            2025                 
  mill…                                                                         
  Gain                                                                          
  (los…                                                                         
  on                                                                            
  exti…                                                                         
  of                                                                            
  debt                                                                          
  reco…                                                                         
  GAAP                                                                          
  Gain                                                                          
  (los…                                                                         
  on            $     —       $     3         $      -1       $     181         
  exti…                                                                         
  of                                                                            
  debt                                                                          
  Gain                                                                          
  (los…                                                                         
  on                  —            -3                 1            -181         
  exti…                                                                         
  of                                                                            
  debt…                                                                         
  Adju…                                                                         
  Gain                                                                          
  (los…                                                                         
  on            $     —       $     —         $       —       $       —         
  exti…                                                                         
  of                                                                            
  debt                                                                          
  (non…                                                                         
  Inte…                                                                         
  expe…                                                                         
  reco…                                                                         
  GAAP                                                                          
  Inte…         $  -398       $  -412         $  -1,196       $  -1,207         
  expe…                                                                         
  Writ…                                                                         
  of                  —            -1                 8             -53         
  fina…                                                                         
  fees…                                                                         
  Adju…                                                                         
  Inte…         $  -398       $  -413         $  -1,188       $  -1,260         
  expe…                                                                         
  (non…                                                                         
  Fore…                                                                         
  exch…                                                                         
  and                                                                           
  other                                                                         
  reco…                                                                         
  GAAP                                                                          
  Fore…                                                                         
  exch…         $    -1       $    -7         $     -19       $     -41         
  and                                                                           
  other                                                                         
  Other                                                                         
  prof…               —            -4                 5             -38         
  fees…                                                                         
  Adju…                                                                         
  Fore…                                                                         
  exch…         $    -1       $   -11         $     -14       $     -79         
  and                                                                           
  other                                                                         
  (non…                                                                         
  Prov…                                                                         
  for                                                                           
  inco…                                                                         
  taxes                                                                         
  reco…                                                                         
  GAAP                                                                          
  Prov…                                                                         
  for           $  -151       $   -37         $    -316       $     -88         
  inco…                                                                         
  taxes                                                                         
  Tax                                                                           
  effe…                                                                         
  of                 -7           -42               -36             -80         
  non-…                                                                         
  adju…                                                                         
  Adju…                                                                         
  Prov…                                                                         
  for           $  -158       $   -79         $    -352       $    -168         
  inco…                                                                         
  taxes                                                                         
  (non…                                                                         
  Net                                                                           
  (inc…                                                                         
  loss                                                                          
  attr…                                                                         
  to                                                                            
  nonc…                                                                         
  inte…                                                                         
  reco…                                                                         
  GAAP                                                                          
  Net                                                                           
  (inc…                                                                         
  loss          $   -10       $    -2         $      -4       $      46         
  attr…                                                                         
  to                                                                            
  nonc…                                                                         
  inte…                                                                         
  Nonc…                                                                         
  inte…                                                                         
  port…                                                                         
  of                 -7            -8               -21             -24         
  amor…                                                                         
  of                                                                            
  inta…                                                                         
  asse…                                                                         
  Nonc…                                                                         
  inte…                                                                         
  port…                                                                         
  of                 -8            -4               -22             -30         
  all                                                                           
  other                                                                         
  adju…                                                                         
  Adju…                                                                         
  net                                                                           
  inco…                                                                         
  attr…         $   -25       $   -14         $     -47       $      -8         
  to                                                                            
  nonc…                                                                         
  inte…                                                                         
  (non…                                                                         
                                                                                
(a) Represents the three components of the non-GAAP adjustment of “Acquisition-
related costs and adjustments (excluding amortization of intangible assets)”
(see Table 2).

(b) Represents the four components of the non-GAAP adjustment of “Other” (see
Table 2).

(c) Represents the one component of the non-GAAP adjustment of “Separation costs
and separation-related costs” (see Table 2).

(d) Represents the two components of the non-GAAP adjustment of “Restructuring,
integration and transformation costs” (see table 2).

(e) Represents the sole component of the non-GAAP adjustment of “Amortization of
intangible assets” (see Table 2).

(f) Represents the sole component of the non-GAAP adjustment of “Goodwill
impairments” (see Table 2).

(g) Represents the sole component of the non-GAAP adjustment of “Litigation and
other matters, net of insurance recoveries and restitutions” (see Table 2).

(h) Represents the sole component of the non-GAAP adjustment of “Gain on sale of
assets, net” (see Table 2).

(i) Represents the sole component of the non-GAAP adjustment of “Asset
impairments” (see Table 2).

(j) Represents the two components of the non-GAAP adjustment of “Gain (loss) on
extinguishment of debt and write-down of financing fees” (see Table 2).

(k) Represents the sole component of the non-GAAP adjustment of “Tax effect of
non-GAAP adjustments” (see Table 2).

(l) Represents the portion of the non-GAAP adjustments attributable to
noncontrolling interest (see Table 2).
17 | Page
                                                                                
  Ba…                                                                           
  He…                                                                           
  Co…                                                                           
  In…                                                                           
  Re…                                                                           
  of                                                                            
  GA…                                                                           
  Net                                                                           
  In…                                                                           
  (L…                                                                           
  to                                                                            
  Ad…                                                                           
  EB…                                                                           
  (n…                                                                           
  For                                                                           
  the                                                                           
  Th…                                                                           
  and                                                                           
  Ni…                                                                           
  Mo…                                                                           
  En…                                                                           
  Se…                                                                           
  30,                                                                           
  20…                                                                           
  and                                                                     Tab…  
  20…                                                                     2b    
 ────────────────────────────────────────────────────────────────────────────── 
  (u…                                                                           
                 Thr…                          Nine                             
                 Mon…                         Mont…                             
                 End…                         Ended                             
                 Sep…                         Sept…                             
                  30,                           30,                             
  (in            2026           2025           2026          2025               
  mi…                                                                           
  Net                                                                           
  in…               $    446       $   181        $  -725       $    223        
  (l…                                                                           
         Int…                                                                   
         exp…            385           397           1,1…          1,168        
         net                                                                    
         Pro…                                                                   
         for             151            37            316             88        
         inc…                                                                   
         tax…                                                                   
         Dep…                                                                   
         and             284           306            860            918        
         amo…                                                                   
  EB…                  1,266           921           1,6…          2,397        
  Ad…                                                                           
         Goo…              —             —           1,4…              —        
         imp…                                                                   
         Ass…              4             1             13              1        
         imp…                                                                   
         Res…                                                                   
         int…                                                                   
         and              16            27             49            108        
         tra…                                                                   
         cos…                                                                   
         Acq…                                                                   
         cos…                                                                   
         and                                                                    
         adj…                                                                   
         (ex…             -1           -11             21             -5        
         amo…                                                                   
         of                                                                     
         int…                                                                   
         ass…                                                                   
         (Ga…                                                                   
         loss                                                                   
         on                —            -3              1           -181        
         ext…                                                                   
         of                                                                     
         debt                                                                   
         Sha…             52            43            158            132        
         com…                                                                   
         Sep…                                                                   
         cos…                                                                   
         and               —            -2              2              5        
         sep…                                                                   
         cos…                                                                   
         Oth…                                                                   
         adj…                                                                   
         Lit…                                                                   
         and                                                                    
         oth…                                                                   
         mat…                                                                   
         net              10            35             26             40        
         of                                                                     
         ins…                                                                   
         rec…                                                                   
         and                                                                    
         res…                                                                   
         Gain                                                                   
         on                                                                     
         sale             -2            -6             -5             -6        
         of                                                                     
         ass…                                                                   
         net                                                                    
         Oth…              5            14             19             74        
  Ad…                                                                           
  EB…                  1,350          1,0…           3,3…          2,565        
  (b)                                                                           
  Ad…                                                                           
  EB…                                                                           
  at…                                                                           
  to                     -45           -33           -106            -76        
  no…                                                                           
  in…                                                                           
  (n…                                                                           
  Ad…                                                                           
  EB…                                                                           
  at…                                                                           
  to                $  1,305       $   986        $  3,2…       $  2,489        
  Ba…                                                                           
  He…                                                                           
  Co…                                                                           
  In…                                                                           
                                                                                
(a) This is a non-GAAP measure. For further information on non-GAAP measures and
non-GAAP ratios, please refer to the “Non-GAAP Information” section of this news
release.

(b) Includes the impact of Acquired IPR&D charges of $0 and $81 million for the
three months ended September 30, 2026 and 2025, respectively, and $16 million
and $110 million for the nine months ended September 30, 2026 and 2025,
respectively.

(c) Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) is Net
(income) loss attributable to noncontrolling interest adjusted for the
noncontrolling interest portion of the adjustments above as follows:
                                                                                
                     Three                          Nine                        
                     Months                         Mont…                       
  (in                Ended   Septe…                 Ended  Septe…               
  mill…              2026       30,    2025         2026      30,    2025       
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  (inc…                                                                         
  loss                                                                          
  attr…              $          -10    $      -2    $          -4    $      46  
  to                                                                            
  nonc…                                                                         
  inte…                                                                         
  Nonc…                                                                         
  inte…                                                                         
  port…                                                                         
  of                                                                            
  adju…                                                                         
  for:                                                                          
           Inter…                                                               
           expen…               -12          -13              -35          -41  
           net                                                                  
           Depre…                                                               
           and                  -13          -13              -39          -39  
           amort…                                                               
           All                                                                  
           other                -10           -5              -28          -42  
           adjus…                                                               
  Adju…                                                                         
  EBIT…                                                                         
  attr…                                                                         
  to                 $          -45    $     -33    $        -106    $     -76  
  nonc…                                                                         
  inte…                                                                         
  (non…                                                                         
                                                                                
(d) Includes the impact of Acquired IPR&D charges net of noncontrolling interest
(non-GAAP) of $0 and $81 million for the three months ended September 30, 2026
and 2025, respectively and $14 million and $106 million for the nine months
ended September 30, 2026 and 2025, respectively.
18 | Page
                                                                                
                                                                                
 ────────────────────────────────────────────────────────────────────────────── 
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
(a) The impact for changes in foreign currency exchange rates is determined as
the difference in the current period reported revenues at their current period
currency exchange rates and the current period reported revenues revalued using
the monthly average currency exchange rates during the comparable prior period.

(b) This is a non-GAAP measure. For further information on non-GAAP measures and
non-GAAP ratios, please refer to the “Non-GAAP Information” section of this news
release.
19 | Page
                                                                                
                                                                                
 ────────────────────────────────────────────────────────────────────────────── 
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
(a) The impact for changes in foreign currency exchange rates is determined as
the difference in the current period reported revenues at their current period
currency exchange rates and the current period reported revenues revalued using
the monthly average currency exchange rates during the comparable prior period.

(b) This is a non-GAAP measure. For further information on non-GAAP measures and
non-GAAP ratios, please refer to the “Non-GAAP Information” section of this news
release.
20 | Page
                                                                                
  Baus…                                                                         
  Heal…                                                                         
  Comp…                                                                         
  Inc.                                                                          
  Other                                                                         
  Fina…                                                                         
  Info…                                                                         
  (una…                                                                         
  (in                                                                           
  mill…                                                                         
  Cash,                                                                         
  Cash                                                                          
  Equi…                                                                         
  and                                  Septe…            Decem…                 
  Rest…                                   30,               31,          Table  
  Cash                                   2026              2025          4      
 ────────────────────────────────────────────────────────────────────────────── 
  Cash                                                                          
  and                                       $   2,485         $   1,309         
  cash                                                                          
  equi…                                                                         
  Rest…                                             3                16         
  cash                                                                          
  Cash,                                                                         
  cash                                                                          
  equi…                                     $   2,488         $   1,325         
  and                                                                           
  rest…                                                                         
  cash                                                                          
  Debt                                                                          
  Obli…                                                                         
  Seni…                                                                         
  Secu…                                                                         
  Cred…                                                                         
  Faci…                                                                         
  Revo…                                                                         
  Cred…                                     $     100         $     100         
  Faci…                                                                         
  Term                                                                          
  Loan                                          5,750             5,787         
  Faci…                                                                         
  Seni…                                                                         
  Secu…                                        10,208            10,235         
  Notes                                                                         
  Seni…                                                                         
  Unse…                                         4,098             4,098         
  Notes                                                                         
  Other                                            12                12         
  Total                                                                         
  long…                                                                         
  debt                                                                          
  and                                                                           
  othe…                                                                         
  net                                          20,168            20,232         
  of                                                                            
  prem…                                                                         
  disc…                                                                         
  and                                                                           
  issu…                                                                         
  costs                                                                         
  Plus:                                                                         
  Unam…                                                                         
  prem…                                                                         
  disc…                                           469               585         
  and                                                                           
  issu…                                                                         
  costs                                                                         
  Total                                                                         
  long…                                                                         
  debt                                      $  20,637         $  20,817         
  and                                                                           
  other                                                                         
  Matu…                                                                         
  of                                                                            
  Debt                                                                          
  Obli…                                                                         
  (at                                                                           
  prin…                                                                         
  amou…                                                                         
  Rema…                                                                         
  of                                        $      15         $      58         
  2026                                                                          
  2027                                            701               701         
  2028                                          3,766             4,240         
  2029                                          1,667             1,662         
  2030                                          4,123             4,118         
  2031                                          3,896             3,453         
  Ther…                                         6,000             6,000         
  Total                                                                         
  debt                                      $  20,168         $  20,232         
  obli…                                                                         
            Three                        Nine                                   
           Months                      Months                                   
            Ended                       Ended                                   
           Septe…                      Septe…                                   
              30,                         30,                                   
  (in        2026         2025           2026              2025                 
  mill…                                                                         
  Cash                                                                          
  prov…                                                                         
  by            $  813       $  405         $   1,714         $     905         
  oper…                                                                         
  acti…                                                                         
  Net                                                                           
  cash                                                                          
  impa…                                                                         
  of                 —           87               167               186         
  lega…                                                                         
  legal                                                                         
  sett…                                                                         
  Paym…                                                                         
  of                12           22                26                44         
  tran…                                                                         
  costs                                                                         
  Paym…                                                                         
  of                                                                            
  sepa…                                                                         
  costs              —            1                 —                13         
  and                                                                           
  sepa…                                                                         
  costs                                                                         
  Inte…                                                                         
  paym…                                                                         
  char…            -44          -87              -144              -251         
  agai…                                                                         
  debt                                                                          
  prem…                                                                         
  Fees                                                                          
  paid                                                                          
  in                                                                            
  conn…              —            5                13                88         
  with                                                                          
  debt                                                                          
  refi…                                                                         
  Paym…                                                                         
  of                 1           75                17               103         
  acqu…                                                                         
  IPR&D                                                                         
  Adju…                                                                         
  cash                                                                          
  flows         $  782       $  508         $   1,793         $   1,088         
  from                                                                          
  oper…                                                                         
                                                                                
( a) Payments of legacy legal settlements, net of insurance recoveries and
restitutions.

(b) This is a non-GAAP measure. For further information on non-GAAP measures and
non-GAAP ratios, please refer to the “Non-GAAP Information” section of this news
release.
21 | Page
                                                                                
  Bausch                                                                        
  Health       Three                                                            
  Companies    Months                                                           
  Inc.         Ended                                                            
  Other        September                                                        
  Financial    30, 2026                             Bausch                      
  Informat…    Bausch                               Health                      
  (unaudit…    Health                               (excl.                      
  (in          Companies          Bausch +          B+L)(a),         Table 4    
  millions)    Inc.               Lomb(a)           (b)              (continu…  
 ────────────────────────────────────────────────────────────────────────────── 
  Cash                                                                          
  provided                                                                      
  by           $           813    $          233    $           581             
  operating                                                                     
  activiti…                                                                     
  Payments                                                                      
  of                        12                11                  1             
  transfor…                                                                     
  costs                                                                         
  Interest                                                                      
  payments                                                                      
  charged                  -44                 —                -44             
  against                                                                       
  debt                                                                          
  premium                                                                       
  Payments                                                                      
  of                         1                 —                  1             
  acquired                                                                      
  IPR&D                                                                         
  Adjusted                                                                      
  cash                                                                          
  flows        $           782    $          244    $           539             
  from                                                                          
  operatio…                                                                     
                                                                                
(a) This is a non-GAAP measure. Management considers the presentation of
Adjusted cash flows from operations for Bausch Health (excl. B+L) (non-GAAP) to
be meaningful information and utilizes it in decision making and for
compensation purposes. Adjusted cash flows from operations for Bausch Health
(excl. B+L) (non-GAAP) is not intended to be representative of GAAP operating
activities and Adjusted cash flows from operations for B+L (non-GAAP) is not
intended to be representative of discontinued operations as the criteria for
that accounting has not been met. As such, Adjusted cash flows from operations
excluding B+L (non-GAAP) as included herein may not be indicative of the results
of the operations or Adjusted cash flows from operations attributable to Bausch
Health (non-GAAP) in the future, or if B+L met the criteria to be treated as a
discontinued operation during any of the periods presented.

(b) Amounts may not cross foot due to rounding.
22 | Page
                                                                                
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                         T…  
  …                                                                         5   
 ────────────────────────────────────────────────────────────────────────────── 
  …                                                                             
             T…                              T…                                 
             M…                              M…                                 
             E…                              E…                                 
             S…                              S…                                 
             3…                              3…                                 
             2…                              2…                                 
             B…        B…         B…         B…         B…         B…           
  …          H…        +          H…         H…         +          H…           
  …          C…        L…         (…         C…         L…         (…           
             I…                   B…         I…                    B…           
  …                                                                             
  …          $   4…    $    35    $   411    $   181    $   -25    $   206      
  …                                                                             
       I…                                                                       
       e…        3…         93        292        397         98        299      
       n…                                                                       
       P…                                                                       
       f…        1…         23        128         37         22         15      
       i…                                                                       
       t…                                                                       
       D…                                                                       
       a…        2…        102        182        306        109        197      
       a…                                                                       
  …              1…        253        1,…        921        204        717      
  …                                                                             
       A…         4          4          —          1          —          1      
       i…                                                                       
       R…                                                                       
       i…                                                                       
       a…        16         12          4         27         20          7      
       t…                                                                       
       c…                                                                       
       A…                                                                       
       c…                                                                       
       a…                                                                       
       a…                                                                       
       (…        -1          9        -10        -11         -2         -9      
       a…                                                                       
       of                                                                       
       i…                                                                       
       a…                                                                       
       G…                                                                       
       on                                                                       
       e…         —          —          —         -3         -3          —      
       of                                                                       
       d…                                                                       
       S…        52         37         15         43         27         16      
       c…                                                                       
       S…                                                                       
       c…                                                                       
       a…         —          —          —         -2         -2          —      
       s…                                                                       
       c…                                                                       
       O…                                                                       
       a…                                                                       
       L…                                                                       
       a…                                                                       
       o…                                                                       
       m…                                                                       
       n…        10          8          2         35          1         34      
       of                                                                       
       i…                                                                       
       r…                                                                       
       a…                                                                       
       r…                                                                       
       G…                                                                       
       on                                                                       
       s…        -2          —         -2         -6         -6          —      
       of                                                                       
       a…                                                                       
       n…                                                                       
       O…         5          5          —         14          7          7      
  …          $   1…    $   328    $   1,…    $   1,…    $   246    $   773      
  …                                                                             
  …                                                                             
  …          $    —    $     —    $     —    $    81    $     —    $    81      
  …                                                                             
  …                                                                             
                                                                                
(a) This is a non-GAAP measure. Management considers the presentation of
Adjusted EBITDA for Bausch Health (excluding B+L) (non-GAAP) to be meaningful
information and utilizes it in decision making and for compensation purposes.
Adjusted EBITDA for Bausch Health Excluding B+L (non-GAAP) is not intended to be
representative of GAAP continuing operations and Adjusted EBITDA for B+L is not
intended to be representative of discontinued operations as the criteria for
that accounting has not been met. As such, Adjusted EBITDA for Bausch Health
excluding B+L (non-GAAP) as included herein may not be indicative of the results
of the operations or Adjusted EBITDA attributable to Bausch Health (non-GAAP) in
the future, or if B+L met the criteria to be treated as a discontinued operation
during any of the periods presented.

(b) Adjusted EBITDA (non-GAAP) above includes Adjusted EBITDA attributable to
noncontrolling interests. For Bausch Health Companies Inc., this amounted to $45
million and $33 million for the three months ended September 30, 2026 and 2025,
respectively, which includes $3 million related to B+L in each period.
23 | Page

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BHC/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.